JP2011520989A - インターロイキン−２１受容体の結合性タンパク質を利用する治療法 - Google Patents

Info

Publication number

JP2011520989A

JP2011520989A JP2011510745A JP2011510745A JP2011520989A JP 2011520989 A JP2011520989 A JP 2011520989A JP 2011510745 A JP2011510745 A JP 2011510745A JP 2011510745 A JP2011510745 A JP 2011510745A JP 2011520989 A JP2011520989 A JP 2011520989A

Authority

JP

Japan

Prior art keywords

binding

human

antigen

antibody

binding protein

Prior art date

2008-05-23

Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)

Pending

Links

• Espacenet
• Global Dossier
• Discuss

• 238000002560 therapeutic procedure Methods 0.000 title description 2
• 108091009330 interleukin-21 receptor binding proteins Proteins 0.000 title 1
• 108091008324 binding proteins Proteins 0.000 claims abstract description 334
• 230000027455 binding Effects 0.000 claims abstract description 283
• 241000282414 Homo sapiens Species 0.000 claims abstract description 237
• 239000012634 fragment Substances 0.000 claims abstract description 173
• 239000000427 antigen Substances 0.000 claims abstract description 154
• 108091007433 antigens Proteins 0.000 claims abstract description 153
• 102000036639 antigens Human genes 0.000 claims abstract description 153
• 238000000034 method Methods 0.000 claims abstract description 139
• 101001010593 Homo sapiens Interleukin-21 receptor Proteins 0.000 claims abstract description 70
• 230000000694 effects Effects 0.000 claims abstract description 59
• 230000001404 mediated effect Effects 0.000 claims abstract description 27
• 206010052779 Transplant rejections Diseases 0.000 claims abstract description 15
• 208000023275 Autoimmune disease Diseases 0.000 claims abstract description 9
• 206010020751 Hypersensitivity Diseases 0.000 claims abstract description 9
• 230000007815 allergy Effects 0.000 claims abstract description 9
• 102000023732 binding proteins Human genes 0.000 claims abstract 43
• 210000004027 cell Anatomy 0.000 claims description 218
• 108010074108 interleukin-21 Proteins 0.000 claims description 156
• 108090000623 proteins and genes Proteins 0.000 claims description 137
• 125000003275 alpha amino acid group Chemical group 0.000 claims description 109
• 102000004169 proteins and genes Human genes 0.000 claims description 72
• 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 claims description 71
• 230000035755 proliferation Effects 0.000 claims description 60
• 230000014509 gene expression Effects 0.000 claims description 47
• 210000004369 blood Anatomy 0.000 claims description 33
• 239000008280 blood Substances 0.000 claims description 33
• 210000003719 b-lymphocyte Anatomy 0.000 claims description 32
• 239000002773 nucleotide Substances 0.000 claims description 32
• 125000003729 nucleotide group Chemical group 0.000 claims description 32
• 102100030703 Interleukin-22 Human genes 0.000 claims description 28
• 201000010099 disease Diseases 0.000 claims description 26
• 239000003446 ligand Substances 0.000 claims description 23
• 230000004663 cell proliferation Effects 0.000 claims description 16
• 102000008640 interleukin-21 receptor activity proteins Human genes 0.000 claims description 14
• 108040002099 interleukin-21 receptor activity proteins Proteins 0.000 claims description 14
• 206010039073 rheumatoid arthritis Diseases 0.000 claims description 14
• 230000001225 therapeutic effect Effects 0.000 claims description 14
• 102100024222 B-lymphocyte antigen CD19 Human genes 0.000 claims description 13
• 101000980825 Homo sapiens B-lymphocyte antigen CD19 Proteins 0.000 claims description 13
• 108090001005 Interleukin-6 Proteins 0.000 claims description 13
• 102000004889 Interleukin-6 Human genes 0.000 claims description 12
• 210000002865 immune cell Anatomy 0.000 claims description 12
• 230000003285 pharmacodynamic effect Effects 0.000 claims description 12
• 102100030385 Granzyme B Human genes 0.000 claims description 11
• 101001009603 Homo sapiens Granzyme B Proteins 0.000 claims description 11
• 101000987581 Homo sapiens Perforin-1 Proteins 0.000 claims description 11
• 102100028467 Perforin-1 Human genes 0.000 claims description 11
• 201000000596 systemic lupus erythematosus Diseases 0.000 claims description 11
• 108090000174 Interleukin-10 Proteins 0.000 claims description 9
• 102000003814 Interleukin-10 Human genes 0.000 claims description 9
• 108010017324 STAT3 Transcription Factor Proteins 0.000 claims description 9
• 201000006417 multiple sclerosis Diseases 0.000 claims description 9
• 108090001007 Interleukin-8 Proteins 0.000 claims description 7
• 102000004890 Interleukin-8 Human genes 0.000 claims description 7
• 108091011896 CSF1 Proteins 0.000 claims description 6
• 101000713602 Homo sapiens T-box transcription factor TBX21 Proteins 0.000 claims description 6
• 102100028123 Macrophage colony-stimulating factor 1 Human genes 0.000 claims description 6
• 102100036840 T-box transcription factor TBX21 Human genes 0.000 claims description 6
• 230000002917 arthritic effect Effects 0.000 claims description 6
• 230000003463 hyperproliferative effect Effects 0.000 claims description 6
• 101100005713 Homo sapiens CD4 gene Proteins 0.000 claims description 4
• 201000004681 Psoriasis Diseases 0.000 claims description 4
• 230000008859 change Effects 0.000 claims description 4
• 239000002253 acid Substances 0.000 claims description 3
• 230000004968 inflammatory condition Effects 0.000 claims description 2
• 102000004495 STAT3 Transcription Factor Human genes 0.000 claims 2
• 108010017411 Interleukin-21 Receptors Proteins 0.000 abstract description 174
• 239000005557 antagonist Substances 0.000 abstract description 35
• 239000000203 mixture Substances 0.000 abstract description 33
• 238000011282 treatment Methods 0.000 abstract description 29
• 230000028993 immune response Effects 0.000 abstract description 10
• 208000026278 immune system disease Diseases 0.000 abstract description 10
• 208000027866 inflammatory disease Diseases 0.000 abstract description 5
• 238000003745 diagnosis Methods 0.000 abstract description 2
• 102000004527 Interleukin-21 Receptors Human genes 0.000 abstract 4
• 230000006806 disease prevention Effects 0.000 abstract 1
• 102000047008 human IL21R Human genes 0.000 abstract 1
• 102000014914 Carrier Proteins Human genes 0.000 description 291
• 102100030699 Interleukin-21 receptor Human genes 0.000 description 165
• 102100030704 Interleukin-21 Human genes 0.000 description 133
• 241000699670 Mus sp. Species 0.000 description 112
• 101710117290 Aldo-keto reductase family 1 member C4 Proteins 0.000 description 72
• 102100024952 Protein CBFA2T1 Human genes 0.000 description 72
• 241000699666 Mus <mouse, genus> Species 0.000 description 71
• 150000007523 nucleic acids Chemical class 0.000 description 70
• 235000018102 proteins Nutrition 0.000 description 63
• 108090000765 processed proteins & peptides Proteins 0.000 description 60
• FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 48
• 241001465754 Metazoa Species 0.000 description 47
• 102000004196 processed proteins & peptides Human genes 0.000 description 46
• 208000035475 disorder Diseases 0.000 description 45
• 229920001184 polypeptide Polymers 0.000 description 41
• 238000006386 neutralization reaction Methods 0.000 description 40
• 239000011780 sodium chloride Substances 0.000 description 40
• 238000002965 ELISA Methods 0.000 description 39
• 210000001744 T-lymphocyte Anatomy 0.000 description 39
• 210000002966 serum Anatomy 0.000 description 37
• 241000282567 Macaca fascicularis Species 0.000 description 36
• 238000003556 assay Methods 0.000 description 36
• 101001010621 Homo sapiens Interleukin-21 Proteins 0.000 description 33
• 241000700159 Rattus Species 0.000 description 33
• 102000004127 Cytokines Human genes 0.000 description 31
• 108090000695 Cytokines Proteins 0.000 description 31
• 235000001014 amino acid Nutrition 0.000 description 31
• 230000001419 dependent effect Effects 0.000 description 30
• 239000003112 inhibitor Substances 0.000 description 30
• 229910052720 vanadium Inorganic materials 0.000 description 30
• 101001010620 Mus musculus Interleukin-21 Proteins 0.000 description 29
• 102000039446 nucleic acids Human genes 0.000 description 28
• 108020004707 nucleic acids Proteins 0.000 description 28
• 102000040430 polynucleotide Human genes 0.000 description 28
• 108091033319 polynucleotide Proteins 0.000 description 28
• 239000002157 polynucleotide Substances 0.000 description 28
• 210000004978 chinese hamster ovary cell Anatomy 0.000 description 26
• 239000003814 drug Substances 0.000 description 24
• 238000006467 substitution reaction Methods 0.000 description 24
• 108090000176 Interleukin-13 Proteins 0.000 description 23
• 102000003816 Interleukin-13 Human genes 0.000 description 23
• 101001010584 Mus musculus Interleukin-21 receptor Proteins 0.000 description 23
• 238000012054 celltiter-glo Methods 0.000 description 23
• 210000004602 germ cell Anatomy 0.000 description 23
• 108060003951 Immunoglobulin Proteins 0.000 description 22
• 210000004712 air sac Anatomy 0.000 description 22
• 150000001413 amino acids Chemical class 0.000 description 22
• 108020001507 fusion proteins Proteins 0.000 description 22
• 102000037865 fusion proteins Human genes 0.000 description 22
• 102000018358 immunoglobulin Human genes 0.000 description 22
• 238000001990 intravenous administration Methods 0.000 description 22
• 229940024606 amino acid Drugs 0.000 description 21
• 239000003795 chemical substances by application Substances 0.000 description 21
• 238000009396 hybridization Methods 0.000 description 21
• 230000008595 infiltration Effects 0.000 description 21
• 238000001764 infiltration Methods 0.000 description 21
• 239000000523 sample Substances 0.000 description 20
• 229940124597 therapeutic agent Drugs 0.000 description 20
• 108020004414 DNA Proteins 0.000 description 19
• 238000004364 calculation method Methods 0.000 description 19
• -1 IFNγ Proteins 0.000 description 18
• 241000124008 Mammalia Species 0.000 description 18
• 108010001336 Horseradish Peroxidase Proteins 0.000 description 17
• 241001529936 Murinae Species 0.000 description 17
• 238000002474 experimental method Methods 0.000 description 17
• 210000004698 lymphocyte Anatomy 0.000 description 17
• 238000011002 quantification Methods 0.000 description 17
• 102000005962 receptors Human genes 0.000 description 17
• 108020003175 receptors Proteins 0.000 description 17
• 230000004044 response Effects 0.000 description 17
• 101000611183 Homo sapiens Tumor necrosis factor Proteins 0.000 description 16
• 230000005875 antibody response Effects 0.000 description 16
• 101000716102 Homo sapiens T-cell surface glycoprotein CD4 Proteins 0.000 description 15
• 102100036011 T-cell surface glycoprotein CD4 Human genes 0.000 description 15
• 102100040247 Tumor necrosis factor Human genes 0.000 description 15
• 210000003734 kidney Anatomy 0.000 description 15
• 108010047041 Complementarity Determining Regions Proteins 0.000 description 14
• 241000283984 Rodentia Species 0.000 description 14
• 206010003246 arthritis Diseases 0.000 description 14
• 239000000872 buffer Substances 0.000 description 14
• 238000010494 dissociation reaction Methods 0.000 description 14
• 230000005593 dissociations Effects 0.000 description 14
• 210000001519 tissue Anatomy 0.000 description 14
• 241000282412 Homo Species 0.000 description 13
• 238000000338 in vitro Methods 0.000 description 13
• 239000000047 product Substances 0.000 description 13
• 108091028043 Nucleic acid sequence Proteins 0.000 description 12
• 150000001720 carbohydrates Chemical group 0.000 description 12
• 230000007423 decrease Effects 0.000 description 12
• 238000001727 in vivo Methods 0.000 description 12
• 238000007912 intraperitoneal administration Methods 0.000 description 12
• 230000003472 neutralizing effect Effects 0.000 description 12
• 241000894007 species Species 0.000 description 12
• 108090000172 Interleukin-15 Proteins 0.000 description 11
• 238000004458 analytical method Methods 0.000 description 11
• 238000009826 distribution Methods 0.000 description 11
• 230000006870 function Effects 0.000 description 11
• 230000012010 growth Effects 0.000 description 11
• 230000005764 inhibitory process Effects 0.000 description 11
• HQKMJHAJHXVSDF-UHFFFAOYSA-L magnesium stearate Chemical compound [Mg+2].CCCCCCCCCCCCCCCCCC([O-])=O.CCCCCCCCCCCCCCCCCC([O-])=O HQKMJHAJHXVSDF-UHFFFAOYSA-L 0.000 description 11
• 230000035772 mutation Effects 0.000 description 11
• 238000012453 sprague-dawley rat model Methods 0.000 description 11
• 108010028780 Complement C3 Proteins 0.000 description 10
• 102000016918 Complement C3 Human genes 0.000 description 10
• 102000004190 Enzymes Human genes 0.000 description 10
• 108090000790 Enzymes Proteins 0.000 description 10
• 102000003812 Interleukin-15 Human genes 0.000 description 10
• 230000015572 biosynthetic process Effects 0.000 description 10
• 239000003102 growth factor Substances 0.000 description 10
• 239000007924 injection Substances 0.000 description 10
• 238000002347 injection Methods 0.000 description 10
• 108040006852 interleukin-4 receptor activity proteins Proteins 0.000 description 10
• 230000004048 modification Effects 0.000 description 10
• 238000012986 modification Methods 0.000 description 10
• 238000003752 polymerase chain reaction Methods 0.000 description 10
• 239000000243 solution Substances 0.000 description 10
• UCSJYZPVAKXKNQ-HZYVHMACSA-N streptomycin Chemical compound CN[C@H]1[C@H](O)[C@@H](O)[C@H](CO)O[C@H]1O[C@@H]1[C@](C=O)(O)[C@H](C)O[C@H]1O[C@@H]1[C@@H](NC(N)=N)[C@H](O)[C@@H](NC(N)=N)[C@H](O)[C@H]1O UCSJYZPVAKXKNQ-HZYVHMACSA-N 0.000 description 10
• 239000000126 substance Substances 0.000 description 10
• 241000283690 Bos taurus Species 0.000 description 9
• 108010087819 Fc receptors Proteins 0.000 description 9
• 102000009109 Fc receptors Human genes 0.000 description 9
• 108010065805 Interleukin-12 Proteins 0.000 description 9
• 102000013462 Interleukin-12 Human genes 0.000 description 9
• 102100034922 T-cell surface glycoprotein CD8 alpha chain Human genes 0.000 description 9
• 125000000539 amino acid group Chemical group 0.000 description 9
• 238000006243 chemical reaction Methods 0.000 description 9
• 238000001514 detection method Methods 0.000 description 9
• QFJCIRLUMZQUOT-HPLJOQBZSA-N sirolimus Chemical compound C1C[C@@H](O)[C@H](OC)C[C@@H]1C[C@@H](C)[C@H]1OC(=O)[C@@H]2CCCCN2C(=O)C(=O)[C@](O)(O2)[C@H](C)CC[C@H]2C[C@H](OC)/C(C)=C/C=C/C=C/[C@@H](C)C[C@@H](C)C(=O)[C@H](OC)[C@H](O)/C(C)=C/[C@@H](C)C(=O)C1 QFJCIRLUMZQUOT-HPLJOQBZSA-N 0.000 description 9
• 238000012360 testing method Methods 0.000 description 9
• 239000013598 vector Substances 0.000 description 9
• 241000282693 Cercopithecidae Species 0.000 description 8
• 241000283973 Oryctolagus cuniculus Species 0.000 description 8
• 230000037396 body weight Effects 0.000 description 8
• 210000004556 brain Anatomy 0.000 description 8
• 230000000295 complement effect Effects 0.000 description 8
• 238000000151 deposition Methods 0.000 description 8
• 210000002472 endoplasmic reticulum Anatomy 0.000 description 8
• 230000004927 fusion Effects 0.000 description 8
• 230000013595 glycosylation Effects 0.000 description 8
• 238000006206 glycosylation reaction Methods 0.000 description 8
• 238000004519 manufacturing process Methods 0.000 description 8
• 239000008194 pharmaceutical composition Substances 0.000 description 8
• ZAHRKKWIAAJSAO-UHFFFAOYSA-N rapamycin Natural products COCC(O)C(=C/C(C)C(=O)CC(OC(=O)C1CCCCN1C(=O)C(=O)C2(O)OC(CC(OC)C(=CC=CC=CC(C)CC(C)C(=O)C)C)CCC2C)C(C)CC3CCC(O)C(C3)OC)C ZAHRKKWIAAJSAO-UHFFFAOYSA-N 0.000 description 8
• 229960002930 sirolimus Drugs 0.000 description 8
• 229960000814 tetanus toxoid Drugs 0.000 description 8
• 238000010600 3H thymidine incorporation assay Methods 0.000 description 7
• 241000287828 Gallus gallus Species 0.000 description 7
• 101001055144 Homo sapiens Interleukin-2 receptor subunit alpha Proteins 0.000 description 7
• 108010002350 Interleukin-2 Proteins 0.000 description 7
• 102000000588 Interleukin-2 Human genes 0.000 description 7
• 102100024040 Signal transducer and activator of transcription 3 Human genes 0.000 description 7
• 230000010056 antibody-dependent cellular cytotoxicity Effects 0.000 description 7
• 235000014633 carbohydrates Nutrition 0.000 description 7
• 235000013330 chicken meat Nutrition 0.000 description 7
• 239000003636 conditioned culture medium Substances 0.000 description 7
• 230000008021 deposition Effects 0.000 description 7
• 239000012636 effector Substances 0.000 description 7
• 238000003365 immunocytochemistry Methods 0.000 description 7
• 238000010186 staining Methods 0.000 description 7
• 238000002198 surface plasmon resonance spectroscopy Methods 0.000 description 7
• YBJHBAHKTGYVGT-ZKWXMUAHSA-N (+)-Biotin Chemical compound N1C(=O)N[C@@H]2[C@H](CCCCC(=O)O)SC[C@@H]21 YBJHBAHKTGYVGT-ZKWXMUAHSA-N 0.000 description 6
• NHBKXEKEPDILRR-UHFFFAOYSA-N 2,3-bis(butanoylsulfanyl)propyl butanoate Chemical compound CCCC(=O)OCC(SC(=O)CCC)CSC(=O)CCC NHBKXEKEPDILRR-UHFFFAOYSA-N 0.000 description 6
• 241000251468 Actinopterygii Species 0.000 description 6
• 235000002198 Annona diversifolia Nutrition 0.000 description 6
• 241000282836 Camelus dromedarius Species 0.000 description 6
• 241000251730 Chondrichthyes Species 0.000 description 6
• DHMQDGOQFOQNFH-UHFFFAOYSA-N Glycine Chemical compound NCC(O)=O DHMQDGOQFOQNFH-UHFFFAOYSA-N 0.000 description 6
• WZUVPPKBWHMQCE-UHFFFAOYSA-N Haematoxylin Chemical compound C12=CC(O)=C(O)C=C2CC2(O)C1C1=CC=C(O)C(O)=C1OC2 WZUVPPKBWHMQCE-UHFFFAOYSA-N 0.000 description 6
• 101000914484 Homo sapiens T-lymphocyte activation antigen CD80 Proteins 0.000 description 6
• 206010061218 Inflammation Diseases 0.000 description 6
• 102000003810 Interleukin-18 Human genes 0.000 description 6
• 108090000171 Interleukin-18 Proteins 0.000 description 6
• 206010028980 Neoplasm Diseases 0.000 description 6
• 102100027222 T-lymphocyte activation antigen CD80 Human genes 0.000 description 6
• 238000007792 addition Methods 0.000 description 6
• 125000003295 alanine group Chemical group N[C@@H](C)C(=O)* 0.000 description 6
• 208000006673 asthma Diseases 0.000 description 6
• 229910002091 carbon monoxide Inorganic materials 0.000 description 6
• 238000001516 cell proliferation assay Methods 0.000 description 6
• KRKNYBCHXYNGOX-UHFFFAOYSA-N citric acid Chemical compound OC(=O)CC(O)(C(O)=O)CC(O)=O KRKNYBCHXYNGOX-UHFFFAOYSA-N 0.000 description 6
• 230000001054 cortical effect Effects 0.000 description 6
• 102000003675 cytokine receptors Human genes 0.000 description 6
• 108010057085 cytokine receptors Proteins 0.000 description 6
• 210000004408 hybridoma Anatomy 0.000 description 6
• 230000036039 immunity Effects 0.000 description 6
• 229940072221 immunoglobulins Drugs 0.000 description 6
• 230000004054 inflammatory process Effects 0.000 description 6
• 230000002401 inhibitory effect Effects 0.000 description 6
• 239000000463 material Substances 0.000 description 6
• 125000002496 methyl group Chemical group [H]C([H])([H])* 0.000 description 6
• 238000010172 mouse model Methods 0.000 description 6
• 238000002823 phage display Methods 0.000 description 6
• 239000013612 plasmid Substances 0.000 description 6
• 239000013641 positive control Substances 0.000 description 6
• 238000002360 preparation method Methods 0.000 description 6
• 230000002829 reductive effect Effects 0.000 description 6
• 230000011664 signaling Effects 0.000 description 6
• 230000008685 targeting Effects 0.000 description 6
• 210000002700 urine Anatomy 0.000 description 6
• QTBSBXVTEAMEQO-UHFFFAOYSA-N Acetic acid Chemical compound CC(O)=O QTBSBXVTEAMEQO-UHFFFAOYSA-N 0.000 description 5
• 206010048998 Acute phase reaction Diseases 0.000 description 5
• 241000283707 Capra Species 0.000 description 5
• 201000004624 Dermatitis Diseases 0.000 description 5
• 208000009386 Experimental Arthritis Diseases 0.000 description 5
• PEDCQBHIVMGVHV-UHFFFAOYSA-N Glycerine Chemical compound OCC(O)CO PEDCQBHIVMGVHV-UHFFFAOYSA-N 0.000 description 5
• 208000009329 Graft vs Host Disease Diseases 0.000 description 5
• 102000006496 Immunoglobulin Heavy Chains Human genes 0.000 description 5
• 108010019476 Immunoglobulin Heavy Chains Proteins 0.000 description 5
• 102100037877 Intercellular adhesion molecule 1 Human genes 0.000 description 5
• 102000000589 Interleukin-1 Human genes 0.000 description 5
• 108010002352 Interleukin-1 Proteins 0.000 description 5
• 102100026878 Interleukin-2 receptor subunit alpha Human genes 0.000 description 5
• 102000004388 Interleukin-4 Human genes 0.000 description 5
• 108090000978 Interleukin-4 Proteins 0.000 description 5
• ZDXPYRJPNDTMRX-VKHMYHEASA-N L-glutamine Chemical compound OC(=O)[C@@H](N)CCC(N)=O ZDXPYRJPNDTMRX-VKHMYHEASA-N 0.000 description 5
• 229930182816 L-glutamine Natural products 0.000 description 5
• FBOZXECLQNJBKD-ZDUSSCGKSA-N L-methotrexate Chemical compound C=1N=C2N=C(N)N=C(N)C2=NC=1CN(C)C1=CC=C(C(=O)N[C@@H](CCC(O)=O)C(O)=O)C=C1 FBOZXECLQNJBKD-ZDUSSCGKSA-N 0.000 description 5
• 229930182555 Penicillin Natural products 0.000 description 5
• JGSARLDLIJGVTE-MBNYWOFBSA-N Penicillin G Chemical compound N([C@H]1[C@H]2SC([C@@H](N2C1=O)C(O)=O)(C)C)C(=O)CC1=CC=CC=C1 JGSARLDLIJGVTE-MBNYWOFBSA-N 0.000 description 5
• 230000004658 acute-phase response Effects 0.000 description 5
• 230000000875 corresponding effect Effects 0.000 description 5
• 238000012217 deletion Methods 0.000 description 5
• 230000037430 deletion Effects 0.000 description 5
• 230000000779 depleting effect Effects 0.000 description 5
• 201000002491 encephalomyelitis Diseases 0.000 description 5
• 208000024908 graft versus host disease Diseases 0.000 description 5
• 238000002868 homogeneous time resolved fluorescence Methods 0.000 description 5
• 230000001900 immune effect Effects 0.000 description 5
• 239000003018 immunosuppressive agent Substances 0.000 description 5
• 230000002757 inflammatory effect Effects 0.000 description 5
• 229960000485 methotrexate Drugs 0.000 description 5
• 210000001616 monocyte Anatomy 0.000 description 5
• 210000000822 natural killer cell Anatomy 0.000 description 5
• 210000000440 neutrophil Anatomy 0.000 description 5
• 229940049954 penicillin Drugs 0.000 description 5
• 238000000746 purification Methods 0.000 description 5
• 238000011160 research Methods 0.000 description 5
• 230000009870 specific binding Effects 0.000 description 5
• 230000000638 stimulation Effects 0.000 description 5
• 229960005322 streptomycin Drugs 0.000 description 5
• 238000007920 subcutaneous administration Methods 0.000 description 5
• 208000024891 symptom Diseases 0.000 description 5
• 239000003981 vehicle Substances 0.000 description 5
• 238000005406 washing Methods 0.000 description 5
• CIWBSHSKHKDKBQ-JLAZNSOCSA-N Ascorbic acid Chemical compound OC[C@H](O)[C@H]1OC(=O)C(O)=C1O CIWBSHSKHKDKBQ-JLAZNSOCSA-N 0.000 description 4
• 108091003079 Bovine Serum Albumin Proteins 0.000 description 4
• 102000017420 CD3 protein, epsilon/gamma/delta subunit Human genes 0.000 description 4
• 108050005493 CD3 protein, epsilon/gamma/delta subunit Proteins 0.000 description 4
• 102100032937 CD40 ligand Human genes 0.000 description 4
• 229920002307 Dextran Polymers 0.000 description 4
• KCXVZYZYPLLWCC-UHFFFAOYSA-N EDTA Chemical compound OC(=O)CN(CC(O)=O)CCN(CC(O)=O)CC(O)=O KCXVZYZYPLLWCC-UHFFFAOYSA-N 0.000 description 4
• 108010054477 Immunoglobulin Fab Fragments Proteins 0.000 description 4
• 102000001706 Immunoglobulin Fab Fragments Human genes 0.000 description 4
• 108010067060 Immunoglobulin Variable Region Proteins 0.000 description 4
• 102000017727 Immunoglobulin Variable Region Human genes 0.000 description 4
• 108010064593 Intercellular Adhesion Molecule-1 Proteins 0.000 description 4
• 108050003558 Interleukin-17 Proteins 0.000 description 4
• 102000013691 Interleukin-17 Human genes 0.000 description 4
• 241000282842 Lama glama Species 0.000 description 4
• 206010062049 Lymphocytic infiltration Diseases 0.000 description 4
• 206010043376 Tetanus Diseases 0.000 description 4
• 239000007983 Tris buffer Substances 0.000 description 4
• 108060008683 Tumor Necrosis Factor Receptor Proteins 0.000 description 4
• 239000012911 assay medium Substances 0.000 description 4
• 230000001580 bacterial effect Effects 0.000 description 4
• 238000004113 cell culture Methods 0.000 description 4
• 238000002648 combination therapy Methods 0.000 description 4
• 150000001875 compounds Chemical class 0.000 description 4
• 239000003246 corticosteroid Substances 0.000 description 4
• 229960001334 corticosteroids Drugs 0.000 description 4
• 231100000599 cytotoxic agent Toxicity 0.000 description 4
• 230000003993 interaction Effects 0.000 description 4
• 229960000681 leflunomide Drugs 0.000 description 4
• VHOGYURTWQBHIL-UHFFFAOYSA-N leflunomide Chemical compound O1N=CC(C(=O)NC=2C=CC(=CC=2)C(F)(F)F)=C1C VHOGYURTWQBHIL-UHFFFAOYSA-N 0.000 description 4
• 230000000670 limiting effect Effects 0.000 description 4
• 125000005647 linker group Chemical group 0.000 description 4
• 210000002540 macrophage Anatomy 0.000 description 4
• 230000002503 metabolic effect Effects 0.000 description 4
• 238000007799 mixed lymphocyte reaction assay Methods 0.000 description 4
• 238000002703 mutagenesis Methods 0.000 description 4
• 231100000350 mutagenesis Toxicity 0.000 description 4
• 229940021182 non-steroidal anti-inflammatory drug Drugs 0.000 description 4
• 230000009871 nonspecific binding Effects 0.000 description 4
• 239000000816 peptidomimetic Substances 0.000 description 4
• 239000000546 pharmaceutical excipient Substances 0.000 description 4
• 239000012071 phase Substances 0.000 description 4
• 229960004641 rituximab Drugs 0.000 description 4
• 230000028327 secretion Effects 0.000 description 4
• 230000004083 survival effect Effects 0.000 description 4
• 238000003786 synthesis reaction Methods 0.000 description 4
• 238000001890 transfection Methods 0.000 description 4
• 230000009261 transgenic effect Effects 0.000 description 4
• LENZDBCJOHFCAS-UHFFFAOYSA-N tris Chemical compound OCC(N)(CO)CO LENZDBCJOHFCAS-UHFFFAOYSA-N 0.000 description 4
• 102000003298 tumor necrosis factor receptor Human genes 0.000 description 4
• XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 4
• MZOFCQQQCNRIBI-VMXHOPILSA-N (3s)-4-[[(2s)-1-[[(2s)-1-[[(1s)-1-carboxy-2-hydroxyethyl]amino]-4-methyl-1-oxopentan-2-yl]amino]-5-(diaminomethylideneamino)-1-oxopentan-2-yl]amino]-3-[[2-[[(2s)-2,6-diaminohexanoyl]amino]acetyl]amino]-4-oxobutanoic acid Chemical compound OC[C@@H](C(O)=O)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CCCN=C(N)N)NC(=O)[C@H](CC(O)=O)NC(=O)CNC(=O)[C@@H](N)CCCCN MZOFCQQQCNRIBI-VMXHOPILSA-N 0.000 description 3
• FWMNVWWHGCHHJJ-SKKKGAJSSA-N 4-amino-1-[(2r)-6-amino-2-[[(2r)-2-[[(2r)-2-[[(2r)-2-amino-3-phenylpropanoyl]amino]-3-phenylpropanoyl]amino]-4-methylpentanoyl]amino]hexanoyl]piperidine-4-carboxylic acid Chemical compound C([C@H](C(=O)N[C@H](CC(C)C)C(=O)N[C@H](CCCCN)C(=O)N1CCC(N)(CC1)C(O)=O)NC(=O)[C@H](N)CC=1C=CC=CC=1)C1=CC=CC=C1 FWMNVWWHGCHHJJ-SKKKGAJSSA-N 0.000 description 3
• WVDDGKGOMKODPV-UHFFFAOYSA-N Benzyl alcohol Chemical compound OCC1=CC=CC=C1 WVDDGKGOMKODPV-UHFFFAOYSA-N 0.000 description 3
• 102100021935 C-C motif chemokine 26 Human genes 0.000 description 3
• 241000282832 Camelidae Species 0.000 description 3
• 108010012236 Chemokines Proteins 0.000 description 3
• 102000019034 Chemokines Human genes 0.000 description 3
• 108091026890 Coding region Proteins 0.000 description 3
• 102000000503 Collagen Type II Human genes 0.000 description 3
• 108010041390 Collagen Type II Proteins 0.000 description 3
• PMATZTZNYRCHOR-CGLBZJNRSA-N Cyclosporin A Chemical compound CC[C@@H]1NC(=O)[C@H]([C@H](O)[C@H](C)C\C=C\C)N(C)C(=O)[C@H](C(C)C)N(C)C(=O)[C@H](CC(C)C)N(C)C(=O)[C@H](CC(C)C)N(C)C(=O)[C@@H](C)NC(=O)[C@H](C)NC(=O)[C@H](CC(C)C)N(C)C(=O)[C@H](C(C)C)NC(=O)[C@H](CC(C)C)N(C)C(=O)CN(C)C1=O PMATZTZNYRCHOR-CGLBZJNRSA-N 0.000 description 3
• 108010036949 Cyclosporine Proteins 0.000 description 3
• WQZGKKKJIJFFOK-QTVWNMPRSA-N D-mannopyranose Chemical compound OC[C@H]1OC(O)[C@@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-QTVWNMPRSA-N 0.000 description 3
• 206010012438 Dermatitis atopic Diseases 0.000 description 3
• 239000006144 Dulbecco’s modified Eagle's medium Substances 0.000 description 3
• 108010008165 Etanercept Proteins 0.000 description 3
• LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 3
• 108010010803 Gelatin Proteins 0.000 description 3
• WQZGKKKJIJFFOK-GASJEMHNSA-N Glucose Natural products OC[C@H]1OC(O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-GASJEMHNSA-N 0.000 description 3
• WHUUTDBJXJRKMK-UHFFFAOYSA-N Glutamic acid Natural products OC(=O)C(N)CCC(O)=O WHUUTDBJXJRKMK-UHFFFAOYSA-N 0.000 description 3
• 101001057956 Homo sapiens 55 kDa erythrocyte membrane protein Proteins 0.000 description 3
• 101000897493 Homo sapiens C-C motif chemokine 26 Proteins 0.000 description 3
• 101000837415 Homo sapiens DNA polymerase subunit gamma-2, mitochondrial Proteins 0.000 description 3
• 101001065272 Homo sapiens EGF-containing fibulin-like extracellular matrix protein 1 Proteins 0.000 description 3
• 101001072202 Homo sapiens Protein disulfide-isomerase Proteins 0.000 description 3
• 101000801228 Homo sapiens Tumor necrosis factor receptor superfamily member 1A Proteins 0.000 description 3
• 102000008394 Immunoglobulin Fragments Human genes 0.000 description 3
• 108010021625 Immunoglobulin Fragments Proteins 0.000 description 3
• 108700005091 Immunoglobulin Genes Proteins 0.000 description 3
• 208000022559 Inflammatory bowel disease Diseases 0.000 description 3
• 108010038453 Interleukin-2 Receptors Proteins 0.000 description 3
• 102000010789 Interleukin-2 Receptors Human genes 0.000 description 3
• 108010002586 Interleukin-7 Proteins 0.000 description 3
• 102000000704 Interleukin-7 Human genes 0.000 description 3
• 102000015696 Interleukins Human genes 0.000 description 3
• 108010063738 Interleukins Proteins 0.000 description 3
• 208000003456 Juvenile Arthritis Diseases 0.000 description 3
• 206010059176 Juvenile idiopathic arthritis Diseases 0.000 description 3
• WHUUTDBJXJRKMK-VKHMYHEASA-N L-glutamic acid Chemical compound OC(=O)[C@@H](N)CCC(O)=O WHUUTDBJXJRKMK-VKHMYHEASA-N 0.000 description 3
• 102000043131 MHC class II family Human genes 0.000 description 3
• 108091054438 MHC class II family Proteins 0.000 description 3
• 201000001263 Psoriatic Arthritis Diseases 0.000 description 3
• 208000036824 Psoriatic arthropathy Diseases 0.000 description 3
• 108020004511 Recombinant DNA Proteins 0.000 description 3
• 108010029477 STAT5 Transcription Factor Proteins 0.000 description 3
• 102100024481 Signal transducer and activator of transcription 5A Human genes 0.000 description 3
• CBPNZQVSJQDFBE-FUXHJELOSA-N Temsirolimus Chemical compound C1C[C@@H](OC(=O)C(C)(CO)CO)[C@H](OC)C[C@@H]1C[C@@H](C)[C@H]1OC(=O)[C@@H]2CCCCN2C(=O)C(=O)[C@](O)(O2)[C@H](C)CC[C@H]2C[C@H](OC)/C(C)=C/C=C/C=C/[C@@H](C)C[C@@H](C)C(=O)[C@H](OC)[C@H](O)/C(C)=C/[C@@H](C)C(=O)C1 CBPNZQVSJQDFBE-FUXHJELOSA-N 0.000 description 3
• 108060008682 Tumor Necrosis Factor Proteins 0.000 description 3
• 102000000852 Tumor Necrosis Factor-alpha Human genes 0.000 description 3
• 230000009471 action Effects 0.000 description 3
• 230000004913 activation Effects 0.000 description 3
• 239000000556 agonist Substances 0.000 description 3
• 208000026935 allergic disease Diseases 0.000 description 3
• 230000003321 amplification Effects 0.000 description 3
• 238000010171 animal model Methods 0.000 description 3
• 239000003242 anti bacterial agent Substances 0.000 description 3
• 230000003110 anti-inflammatory effect Effects 0.000 description 3
• 201000008937 atopic dermatitis Diseases 0.000 description 3
• 230000005784 autoimmunity Effects 0.000 description 3
• WQZGKKKJIJFFOK-VFUOTHLCSA-N beta-D-glucose Chemical compound OC[C@H]1O[C@@H](O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-VFUOTHLCSA-N 0.000 description 3
• 239000011230 binding agent Substances 0.000 description 3
• 238000004166 bioassay Methods 0.000 description 3
• 230000004071 biological effect Effects 0.000 description 3
• 229960002685 biotin Drugs 0.000 description 3
• 235000020958 biotin Nutrition 0.000 description 3
• 239000011616 biotin Substances 0.000 description 3
• 201000011510 cancer Diseases 0.000 description 3
• 230000001413 cellular effect Effects 0.000 description 3
• 238000012512 characterization method Methods 0.000 description 3
• 239000003153 chemical reaction reagent Substances 0.000 description 3
• 208000019069 chronic childhood arthritis Diseases 0.000 description 3
• 229960001265 ciclosporin Drugs 0.000 description 3
• 230000008878 coupling Effects 0.000 description 3
• 238000010168 coupling process Methods 0.000 description 3
• 238000005859 coupling reaction Methods 0.000 description 3
• 230000001461 cytolytic effect Effects 0.000 description 3
• 239000002254 cytotoxic agent Substances 0.000 description 3
• 229940127089 cytotoxic agent Drugs 0.000 description 3
• 229940079593 drug Drugs 0.000 description 3
• 229940073621 enbrel Drugs 0.000 description 3
• 238000005516 engineering process Methods 0.000 description 3
• 239000002532 enzyme inhibitor Substances 0.000 description 3
• YQGOJNYOYNNSMM-UHFFFAOYSA-N eosin Chemical compound [Na+].OC(=O)C1=CC=CC=C1C1=C2C=C(Br)C(=O)C(Br)=C2OC2=C(Br)C(O)=C(Br)C=C21 YQGOJNYOYNNSMM-UHFFFAOYSA-N 0.000 description 3
• 239000000499 gel Substances 0.000 description 3
• 239000008273 gelatin Substances 0.000 description 3
• 229920000159 gelatin Polymers 0.000 description 3
• 235000019322 gelatine Nutrition 0.000 description 3
• 235000011852 gelatine desserts Nutrition 0.000 description 3
• 230000001434 glomerular Effects 0.000 description 3
• 210000002288 golgi apparatus Anatomy 0.000 description 3
• 102000057036 human EFEMP1 Human genes 0.000 description 3
• RAXXELZNTBOGNW-UHFFFAOYSA-N imidazole Natural products C1=CNC=N1 RAXXELZNTBOGNW-UHFFFAOYSA-N 0.000 description 3
• 229940125721 immunosuppressive agent Drugs 0.000 description 3
• 230000006698 induction Effects 0.000 description 3
• 108010074109 interleukin-22 Proteins 0.000 description 3
• 239000007951 isotonicity adjuster Substances 0.000 description 3
• 201000002215 juvenile rheumatoid arthritis Diseases 0.000 description 3
• 238000011813 knockout mouse model Methods 0.000 description 3
• 230000003902 lesion Effects 0.000 description 3
• 210000004072 lung Anatomy 0.000 description 3
• 210000003563 lymphoid tissue Anatomy 0.000 description 3
• 210000004962 mammalian cell Anatomy 0.000 description 3
• 239000011159 matrix material Substances 0.000 description 3
• 235000013336 milk Nutrition 0.000 description 3
• 239000008267 milk Substances 0.000 description 3
• 210000004080 milk Anatomy 0.000 description 3
• 201000008383 nephritis Diseases 0.000 description 3
• 238000003199 nucleic acid amplification method Methods 0.000 description 3
• 201000008482 osteoarthritis Diseases 0.000 description 3
• 230000007170 pathology Effects 0.000 description 3
• 230000037361 pathway Effects 0.000 description 3
• 210000001322 periplasm Anatomy 0.000 description 3
• 229920000642 polymer Polymers 0.000 description 3
• 238000012545 processing Methods 0.000 description 3
• 238000010188 recombinant method Methods 0.000 description 3
• 238000012216 screening Methods 0.000 description 3
• 230000019491 signal transduction Effects 0.000 description 3
• 150000003384 small molecules Chemical class 0.000 description 3
• 239000011734 sodium Substances 0.000 description 3
• 239000006228 supernatant Substances 0.000 description 3
• 239000000725 suspension Substances 0.000 description 3
• 230000008961 swelling Effects 0.000 description 3
• 229960000235 temsirolimus Drugs 0.000 description 3
• 229940104230 thymidine Drugs 0.000 description 3
• 238000011830 transgenic mouse model Methods 0.000 description 3
• 239000011534 wash buffer Substances 0.000 description 3
• 108091032973 (ribonucleotides)n+m Proteins 0.000 description 2
• HZAXFHJVJLSVMW-UHFFFAOYSA-N 2-Aminoethan-1-ol Chemical compound NCCO HZAXFHJVJLSVMW-UHFFFAOYSA-N 0.000 description 2
• HVAUUPRFYPCOCA-AREMUKBSSA-N 2-O-acetyl-1-O-hexadecyl-sn-glycero-3-phosphocholine Chemical compound CCCCCCCCCCCCCCCCOC[C@@H](OC(C)=O)COP([O-])(=O)OCC[N+](C)(C)C HVAUUPRFYPCOCA-AREMUKBSSA-N 0.000 description 2
• KDCGOANMDULRCW-UHFFFAOYSA-N 7H-purine Chemical compound N1=CNC2=NC=NC2=C1 KDCGOANMDULRCW-UHFFFAOYSA-N 0.000 description 2
• 208000036762 Acute promyelocytic leukaemia Diseases 0.000 description 2
• 208000016683 Adult T-cell leukemia/lymphoma Diseases 0.000 description 2
• 102000002260 Alkaline Phosphatase Human genes 0.000 description 2
• 108020004774 Alkaline Phosphatase Proteins 0.000 description 2
• 108010083359 Antigen Receptors Proteins 0.000 description 2
• 102000006306 Antigen Receptors Human genes 0.000 description 2
• 206010003645 Atopy Diseases 0.000 description 2
• 208000032116 Autoimmune Experimental Encephalomyelitis Diseases 0.000 description 2
• 208000034172 Autoimmune Experimental Myasthenia Gravis Diseases 0.000 description 2
• 208000032791 BCR-ABL1 positive chronic myelogenous leukemia Diseases 0.000 description 2
• 108700031361 Brachyury Proteins 0.000 description 2
• 108010029697 CD40 Ligand Proteins 0.000 description 2
• 108090000426 Caspase-1 Proteins 0.000 description 2
• 208000010833 Chronic myeloid leukaemia Diseases 0.000 description 2
• 108020004705 Codon Proteins 0.000 description 2
• 206010009900 Colitis ulcerative Diseases 0.000 description 2
• 241000699800 Cricetinae Species 0.000 description 2
• 208000011231 Crohn disease Diseases 0.000 description 2
• 108010052167 Dihydroorotate Dehydrogenase Proteins 0.000 description 2
• 102100032823 Dihydroorotate dehydrogenase (quinone), mitochondrial Human genes 0.000 description 2
• 108010089072 Dolichyl-diphosphooligosaccharide-protein glycotransferase Proteins 0.000 description 2
• 101100347633 Drosophila melanogaster Mhc gene Proteins 0.000 description 2
• 102100040278 E3 ubiquitin-protein ligase RNF19A Human genes 0.000 description 2
• 102000000509 Estrogen Receptor beta Human genes 0.000 description 2
• 108010041356 Estrogen Receptor beta Proteins 0.000 description 2
• 108091006010 FLAG-tagged proteins Proteins 0.000 description 2
• 239000004471 Glycine Substances 0.000 description 2
• 102000003886 Glycoproteins Human genes 0.000 description 2
• 108090000288 Glycoproteins Proteins 0.000 description 2
• 108010017213 Granulocyte-Macrophage Colony-Stimulating Factor Proteins 0.000 description 2
• 102100039620 Granulocyte-macrophage colony-stimulating factor Human genes 0.000 description 2
• 108010043121 Green Fluorescent Proteins Proteins 0.000 description 2
• 102000004144 Green Fluorescent Proteins Human genes 0.000 description 2
• 208000030836 Hashimoto thyroiditis Diseases 0.000 description 2
• 101000690301 Homo sapiens Aldo-keto reductase family 1 member C4 Proteins 0.000 description 2
• 101000868215 Homo sapiens CD40 ligand Proteins 0.000 description 2
• 101001057504 Homo sapiens Interferon-stimulated gene 20 kDa protein Proteins 0.000 description 2
• 101000736088 Homo sapiens PC4 and SFRS1-interacting protein Proteins 0.000 description 2
• 101001116548 Homo sapiens Protein CBFA2T1 Proteins 0.000 description 2
• 101000738771 Homo sapiens Receptor-type tyrosine-protein phosphatase C Proteins 0.000 description 2
• 101000914514 Homo sapiens T-cell-specific surface glycoprotein CD28 Proteins 0.000 description 2
• 101000801254 Homo sapiens Tumor necrosis factor receptor superfamily member 16 Proteins 0.000 description 2
• 101000801232 Homo sapiens Tumor necrosis factor receptor superfamily member 1B Proteins 0.000 description 2
• 102100025390 Integrin beta-2 Human genes 0.000 description 2
• 108090000177 Interleukin-11 Proteins 0.000 description 2
• 102000003815 Interleukin-11 Human genes 0.000 description 2
• 102000004560 Interleukin-12 Receptors Human genes 0.000 description 2
• 108010017515 Interleukin-12 Receptors Proteins 0.000 description 2
• 108010017535 Interleukin-15 Receptors Proteins 0.000 description 2
• 102000004556 Interleukin-15 Receptors Human genes 0.000 description 2
• 108010002386 Interleukin-3 Proteins 0.000 description 2
• 102000000646 Interleukin-3 Human genes 0.000 description 2
• 108010002335 Interleukin-9 Proteins 0.000 description 2
• 102000000585 Interleukin-9 Human genes 0.000 description 2
• UETNIIAIRMUTSM-UHFFFAOYSA-N Jacareubin Natural products CC1(C)OC2=CC3Oc4c(O)c(O)ccc4C(=O)C3C(=C2C=C1)O UETNIIAIRMUTSM-UHFFFAOYSA-N 0.000 description 2
• SHZGCJCMOBCMKK-DHVFOXMCSA-N L-fucopyranose Chemical compound C[C@@H]1OC(O)[C@@H](O)[C@H](O)[C@@H]1O SHZGCJCMOBCMKK-DHVFOXMCSA-N 0.000 description 2
• 125000002066 L-histidyl group Chemical group [H]N1C([H])=NC(C([H])([H])[C@](C(=O)[*])([H])N([H])[H])=C1[H] 0.000 description 2
• 241000282838 Lama Species 0.000 description 2
• 241000282852 Lama guanicoe Species 0.000 description 2
• 208000006404 Large Granular Lymphocytic Leukemia Diseases 0.000 description 2
• 108010064548 Lymphocyte Function-Associated Antigen-1 Proteins 0.000 description 2
• 206010025323 Lymphomas Diseases 0.000 description 2
• 108010054377 Mannosidases Proteins 0.000 description 2
• 102000001696 Mannosidases Human genes 0.000 description 2
• 208000003926 Myelitis Diseases 0.000 description 2
• 208000033761 Myelogenous Chronic BCR-ABL Positive Leukemia Diseases 0.000 description 2
• OVRNDRQMDRJTHS-FMDGEEDCSA-N N-acetyl-beta-D-glucosamine Chemical compound CC(=O)N[C@H]1[C@H](O)O[C@H](CO)[C@@H](O)[C@@H]1O OVRNDRQMDRJTHS-FMDGEEDCSA-N 0.000 description 2
• 102000008212 P-Selectin Human genes 0.000 description 2
• 108010035766 P-Selectin Proteins 0.000 description 2
• 239000012826 P38 inhibitor Substances 0.000 description 2
• 238000012408 PCR amplification Methods 0.000 description 2
• 229910019142 PO4 Inorganic materials 0.000 description 2
• 241001494479 Pecora Species 0.000 description 2
• 102000035195 Peptidases Human genes 0.000 description 2
• 108091005804 Peptidases Proteins 0.000 description 2
• ISWSIDIOOBJBQZ-UHFFFAOYSA-N Phenol Chemical compound OC1=CC=CC=C1 ISWSIDIOOBJBQZ-UHFFFAOYSA-N 0.000 description 2
• 108010003541 Platelet Activating Factor Proteins 0.000 description 2
• 239000002202 Polyethylene glycol Substances 0.000 description 2
• 208000033766 Prolymphocytic Leukemia Diseases 0.000 description 2
• 208000033826 Promyelocytic Acute Leukemia Diseases 0.000 description 2
• 239000004365 Protease Substances 0.000 description 2
• 108010029485 Protein Isoforms Proteins 0.000 description 2
• 102000001708 Protein Isoforms Human genes 0.000 description 2
• 102100037422 Receptor-type tyrosine-protein phosphatase C Human genes 0.000 description 2
• 239000006146 Roswell Park Memorial Institute medium Substances 0.000 description 2
• 206010039710 Scleroderma Diseases 0.000 description 2
• 238000012300 Sequence Analysis Methods 0.000 description 2
• 108010071390 Serum Albumin Proteins 0.000 description 2
• 102000007562 Serum Albumin Human genes 0.000 description 2
• 208000021386 Sjogren Syndrome Diseases 0.000 description 2
• 208000006045 Spondylarthropathies Diseases 0.000 description 2
• 208000037065 Subacute sclerosing leukoencephalitis Diseases 0.000 description 2
• 206010042297 Subacute sclerosing panencephalitis Diseases 0.000 description 2
• 230000006052 T cell proliferation Effects 0.000 description 2
• 208000031673 T-Cell Cutaneous Lymphoma Diseases 0.000 description 2
• 201000008717 T-cell large granular lymphocyte leukemia Diseases 0.000 description 2
• 102100027213 T-cell-specific surface glycoprotein CD28 Human genes 0.000 description 2
• QJJXYPPXXYFBGM-LFZNUXCKSA-N Tacrolimus Chemical compound C1C[C@@H](O)[C@H](OC)C[C@@H]1\C=C(/C)[C@@H]1[C@H](C)[C@@H](O)CC(=O)[C@H](CC=C)/C=C(C)/C[C@H](C)C[C@H](OC)[C@H]([C@H](C[C@H]2C)OC)O[C@@]2(O)C(=O)C(=O)N2CCCC[C@H]2C(=O)O1 QJJXYPPXXYFBGM-LFZNUXCKSA-N 0.000 description 2
• 201000006704 Ulcerative Colitis Diseases 0.000 description 2
• 108010073929 Vascular Endothelial Growth Factor A Proteins 0.000 description 2
• 102000005789 Vascular Endothelial Growth Factors Human genes 0.000 description 2
• 108010019530 Vascular Endothelial Growth Factors Proteins 0.000 description 2
• 206010047115 Vasculitis Diseases 0.000 description 2
• 241001416177 Vicugna pacos Species 0.000 description 2
• 208000016025 Waldenstroem macroglobulinemia Diseases 0.000 description 2
• 208000033559 Waldenström macroglobulinemia Diseases 0.000 description 2
• 238000010521 absorption reaction Methods 0.000 description 2
• 230000003213 activating effect Effects 0.000 description 2
• 201000006966 adult T-cell leukemia Diseases 0.000 description 2
• 235000004279 alanine Nutrition 0.000 description 2
• 201000009961 allergic asthma Diseases 0.000 description 2
• 150000001412 amines Chemical class 0.000 description 2
• 229960000723 ampicillin Drugs 0.000 description 2
• AVKUERGKIZMTKX-NJBDSQKTSA-N ampicillin Chemical compound C1([C@@H](N)C(=O)N[C@H]2[C@H]3SC([C@@H](N3C2=O)C(O)=O)(C)C)=CC=CC=C1 AVKUERGKIZMTKX-NJBDSQKTSA-N 0.000 description 2
• 230000003042 antagnostic effect Effects 0.000 description 2
• 230000000844 anti-bacterial effect Effects 0.000 description 2
• 229940121363 anti-inflammatory agent Drugs 0.000 description 2
• 239000002260 anti-inflammatory agent Substances 0.000 description 2
• 210000000628 antibody-producing cell Anatomy 0.000 description 2
• 229940121375 antifungal agent Drugs 0.000 description 2
• 239000003429 antifungal agent Substances 0.000 description 2
• 239000003963 antioxidant agent Substances 0.000 description 2
• 235000006708 antioxidants Nutrition 0.000 description 2
• 238000013459 approach Methods 0.000 description 2
• 229960005070 ascorbic acid Drugs 0.000 description 2
• 235000010323 ascorbic acid Nutrition 0.000 description 2
• 239000011668 ascorbic acid Substances 0.000 description 2
• 208000010668 atopic eczema Diseases 0.000 description 2
• 238000002869 basic local alignment search tool Methods 0.000 description 2
• 230000001588 bifunctional effect Effects 0.000 description 2
• 230000008512 biological response Effects 0.000 description 2
• 230000000903 blocking effect Effects 0.000 description 2
• 210000001185 bone marrow Anatomy 0.000 description 2
• 229940098773 bovine serum albumin Drugs 0.000 description 2
• 238000004422 calculation algorithm Methods 0.000 description 2
• 239000006143 cell culture medium Substances 0.000 description 2
• 230000003915 cell function Effects 0.000 description 2
• OSASVXMJTNOKOY-UHFFFAOYSA-N chlorobutanol Chemical compound CC(C)(O)C(Cl)(Cl)Cl OSASVXMJTNOKOY-UHFFFAOYSA-N 0.000 description 2
• MYSWGUAQZAJSOK-UHFFFAOYSA-N ciprofloxacin Chemical compound C12=CC(N3CCNCC3)=C(F)C=C2C(=O)C(C(=O)O)=CN1C1CC1 MYSWGUAQZAJSOK-UHFFFAOYSA-N 0.000 description 2
• 238000010367 cloning Methods 0.000 description 2
• 108010047295 complement receptors Proteins 0.000 description 2
• 102000006834 complement receptors Human genes 0.000 description 2
• 238000005094 computer simulation Methods 0.000 description 2
• 239000013068 control sample Substances 0.000 description 2
• 230000001276 controlling effect Effects 0.000 description 2
• 238000007796 conventional method Methods 0.000 description 2
• 229940111134 coxibs Drugs 0.000 description 2
• 201000007241 cutaneous T cell lymphoma Diseases 0.000 description 2
• 208000004921 cutaneous lupus erythematosus Diseases 0.000 description 2
• 239000003255 cyclooxygenase 2 inhibitor Substances 0.000 description 2
• 229930182912 cyclosporin Natural products 0.000 description 2
• 230000003247 decreasing effect Effects 0.000 description 2
• 230000003111 delayed effect Effects 0.000 description 2
• 210000004443 dendritic cell Anatomy 0.000 description 2
• 206010012601 diabetes mellitus Diseases 0.000 description 2
• 230000004069 differentiation Effects 0.000 description 2
• 238000007865 diluting Methods 0.000 description 2
• 238000010790 dilution Methods 0.000 description 2
• 239000012895 dilution Substances 0.000 description 2
• 239000003937 drug carrier Substances 0.000 description 2
• 238000004520 electroporation Methods 0.000 description 2
• 230000008030 elimination Effects 0.000 description 2
• 238000003379 elimination reaction Methods 0.000 description 2
• 229940125532 enzyme inhibitor Drugs 0.000 description 2
• 210000000267 erythroid cell Anatomy 0.000 description 2
• 239000003797 essential amino acid Substances 0.000 description 2
• 235000020776 essential amino acid Nutrition 0.000 description 2
• 208000012997 experimental autoimmune encephalomyelitis Diseases 0.000 description 2
• 239000012894 fetal calf serum Substances 0.000 description 2
• 238000009472 formulation Methods 0.000 description 2
• 239000003365 glass fiber Substances 0.000 description 2
• 239000008103 glucose Substances 0.000 description 2
• 235000011187 glycerol Nutrition 0.000 description 2
• 239000005090 green fluorescent protein Substances 0.000 description 2
• 230000003394 haemopoietic effect Effects 0.000 description 2
• 201000009277 hairy cell leukemia Diseases 0.000 description 2
• 102000043323 human PSIP1 Human genes 0.000 description 2
• 102000054751 human RUNX1T1 Human genes 0.000 description 2
• 230000003053 immunization Effects 0.000 description 2
• 230000005847 immunogenicity Effects 0.000 description 2
• 230000016784 immunoglobulin production Effects 0.000 description 2
• 229960003444 immunosuppressant agent Drugs 0.000 description 2
• 238000011534 incubation Methods 0.000 description 2
• CGIGDMFJXJATDK-UHFFFAOYSA-N indomethacin Chemical compound CC1=C(CC(O)=O)C2=CC(OC)=CC=C2N1C(=O)C1=CC=C(Cl)C=C1 CGIGDMFJXJATDK-UHFFFAOYSA-N 0.000 description 2
• 238000003780 insertion Methods 0.000 description 2
• 230000037431 insertion Effects 0.000 description 2
• 208000002551 irritable bowel syndrome Diseases 0.000 description 2
• BPHPUYQFMNQIOC-NXRLNHOXSA-N isopropyl beta-D-thiogalactopyranoside Chemical compound CC(C)S[C@@H]1O[C@H](CO)[C@H](O)[C@H](O)[C@H]1O BPHPUYQFMNQIOC-NXRLNHOXSA-N 0.000 description 2
• 208000018937 joint inflammation Diseases 0.000 description 2
• 229950007278 lenercept Drugs 0.000 description 2
• 238000012417 linear regression Methods 0.000 description 2
• 239000002502 liposome Substances 0.000 description 2
• 239000007788 liquid Substances 0.000 description 2
• 238000005567 liquid scintillation counting Methods 0.000 description 2
• 210000001165 lymph node Anatomy 0.000 description 2
• 230000002101 lytic effect Effects 0.000 description 2
• 238000013507 mapping Methods 0.000 description 2
• 238000005259 measurement Methods 0.000 description 2
• 239000002609 medium Substances 0.000 description 2
• GLVAUDGFNGKCSF-UHFFFAOYSA-N mercaptopurine Chemical compound S=C1NC=NC2=C1NC=N2 GLVAUDGFNGKCSF-UHFFFAOYSA-N 0.000 description 2
• KBOPZPXVLCULAV-UHFFFAOYSA-N mesalamine Chemical compound NC1=CC=C(O)C(C(O)=O)=C1 KBOPZPXVLCULAV-UHFFFAOYSA-N 0.000 description 2
• 229960004963 mesalazine Drugs 0.000 description 2
• MYWUZJCMWCOHBA-VIFPVBQESA-N methamphetamine Chemical compound CN[C@@H](C)CC1=CC=CC=C1 MYWUZJCMWCOHBA-VIFPVBQESA-N 0.000 description 2
• LXCFILQKKLGQFO-UHFFFAOYSA-N methylparaben Chemical compound COC(=O)C1=CC=C(O)C=C1 LXCFILQKKLGQFO-UHFFFAOYSA-N 0.000 description 2
• 239000004005 microsphere Substances 0.000 description 2
• 230000003278 mimic effect Effects 0.000 description 2
• 238000010369 molecular cloning Methods 0.000 description 2
• 230000004001 molecular interaction Effects 0.000 description 2
• 238000012544 monitoring process Methods 0.000 description 2
• 210000004877 mucosa Anatomy 0.000 description 2
• 206010028417 myasthenia gravis Diseases 0.000 description 2
• 201000005962 mycosis fungoides Diseases 0.000 description 2
• 239000013642 negative control Substances 0.000 description 2
• 210000005036 nerve Anatomy 0.000 description 2
• 239000002674 ointment Substances 0.000 description 2
• 230000036961 partial effect Effects 0.000 description 2
• 229940124531 pharmaceutical excipient Drugs 0.000 description 2
• 239000010452 phosphate Substances 0.000 description 2
• 229920001223 polyethylene glycol Polymers 0.000 description 2
• NROKBHXJSPEDAR-UHFFFAOYSA-M potassium fluoride Chemical compound [F-].[K+] NROKBHXJSPEDAR-UHFFFAOYSA-M 0.000 description 2
• 239000002243 precursor Substances 0.000 description 2
• 229960005205 prednisolone Drugs 0.000 description 2
• OIGNJSKKLXVSLS-VWUMJDOOSA-N prednisolone Chemical compound O=C1C=C[C@]2(C)[C@H]3[C@@H](O)C[C@](C)([C@@](CC4)(O)C(=O)CO)[C@@H]4[C@@H]3CCC2=C1 OIGNJSKKLXVSLS-VWUMJDOOSA-N 0.000 description 2
• 208000025638 primary cutaneous T-cell non-Hodgkin lymphoma Diseases 0.000 description 2
• 201000001474 proteinuria Diseases 0.000 description 2
• 230000008707 rearrangement Effects 0.000 description 2
• 230000000306 recurrent effect Effects 0.000 description 2
• 230000009467 reduction Effects 0.000 description 2
• 239000013074 reference sample Substances 0.000 description 2
• 238000010187 selection method Methods 0.000 description 2
• 238000012163 sequencing technique Methods 0.000 description 2
• 239000007974 sodium acetate buffer Substances 0.000 description 2
• 239000001509 sodium citrate Substances 0.000 description 2
• NLJMYIDDQXHKNR-UHFFFAOYSA-K sodium citrate Chemical compound O.O.[Na+].[Na+].[Na+].[O-]C(=O)CC(O)(CC([O-])=O)C([O-])=O NLJMYIDDQXHKNR-UHFFFAOYSA-K 0.000 description 2
• DAEPDZWVDSPTHF-UHFFFAOYSA-M sodium pyruvate Chemical compound [Na+].CC(=O)C([O-])=O DAEPDZWVDSPTHF-UHFFFAOYSA-M 0.000 description 2
• 239000002904 solvent Substances 0.000 description 2
• 210000000952 spleen Anatomy 0.000 description 2
• 201000005671 spondyloarthropathy Diseases 0.000 description 2
• 238000010561 standard procedure Methods 0.000 description 2
• 210000000130 stem cell Anatomy 0.000 description 2
• 235000000346 sugar Nutrition 0.000 description 2
• 229960001940 sulfasalazine Drugs 0.000 description 2
• NCEXYHBECQHGNR-QZQOTICOSA-N sulfasalazine Chemical compound C1=C(O)C(C(=O)O)=CC(\N=N\C=2C=CC(=CC=2)S(=O)(=O)NC=2N=CC=CC=2)=C1 NCEXYHBECQHGNR-QZQOTICOSA-N 0.000 description 2
• NCEXYHBECQHGNR-UHFFFAOYSA-N sulfasalazine Natural products C1=C(O)C(C(=O)O)=CC(N=NC=2C=CC(=CC=2)S(=O)(=O)NC=2N=CC=CC=2)=C1 NCEXYHBECQHGNR-UHFFFAOYSA-N 0.000 description 2
• 230000001629 suppression Effects 0.000 description 2
• 210000001258 synovial membrane Anatomy 0.000 description 2
• 210000002437 synoviocyte Anatomy 0.000 description 2
• 230000009885 systemic effect Effects 0.000 description 2
• 231100001274 therapeutic index Toxicity 0.000 description 2
• 238000013518 transcription Methods 0.000 description 2
• 230000035897 transcription Effects 0.000 description 2
• 239000002447 tumor necrosis factor alpha converting enzyme inhibitor Substances 0.000 description 2
• 239000007160 ty medium Substances 0.000 description 2
• 241001430294 unidentified retrovirus Species 0.000 description 2
• 230000002485 urinary effect Effects 0.000 description 2
• 230000003442 weekly effect Effects 0.000 description 2
• DGVVWUTYPXICAM-UHFFFAOYSA-N β‐Mercaptoethanol Chemical compound OCCS DGVVWUTYPXICAM-UHFFFAOYSA-N 0.000 description 2
• HMLGSIZOMSVISS-ONJSNURVSA-N (7r)-7-[[(2z)-2-(2-amino-1,3-thiazol-4-yl)-2-(2,2-dimethylpropanoyloxymethoxyimino)acetyl]amino]-3-ethenyl-8-oxo-5-thia-1-azabicyclo[4.2.0]oct-2-ene-2-carboxylic acid Chemical compound N([C@@H]1C(N2C(=C(C=C)CSC21)C(O)=O)=O)C(=O)\C(=N/OCOC(=O)C(C)(C)C)C1=CSC(N)=N1 HMLGSIZOMSVISS-ONJSNURVSA-N 0.000 description 1
• NFGXHKASABOEEW-UHFFFAOYSA-N 1-methylethyl 11-methoxy-3,7,11-trimethyl-2,4-dodecadienoate Chemical compound COC(C)(C)CCCC(C)CC=CC(C)=CC(=O)OC(C)C NFGXHKASABOEEW-UHFFFAOYSA-N 0.000 description 1
• IIZPXYDJLKNOIY-JXPKJXOSSA-N 1-palmitoyl-2-arachidonoyl-sn-glycero-3-phosphocholine Chemical compound CCCCCCCCCCCCCCCC(=O)OC[C@H](COP([O-])(=O)OCC[N+](C)(C)C)OC(=O)CCC\C=C/C\C=C/C\C=C/C\C=C/CCCCC IIZPXYDJLKNOIY-JXPKJXOSSA-N 0.000 description 1
• ZIIUUSVHCHPIQD-UHFFFAOYSA-N 2,4,6-trimethyl-N-[3-(trifluoromethyl)phenyl]benzenesulfonamide Chemical compound CC1=CC(C)=CC(C)=C1S(=O)(=O)NC1=CC=CC(C(F)(F)F)=C1 ZIIUUSVHCHPIQD-UHFFFAOYSA-N 0.000 description 1
• JKMHFZQWWAIEOD-UHFFFAOYSA-N 2-[4-(2-hydroxyethyl)piperazin-1-yl]ethanesulfonic acid Chemical compound OCC[NH+]1CCN(CCS([O-])(=O)=O)CC1 JKMHFZQWWAIEOD-UHFFFAOYSA-N 0.000 description 1
• 125000000979 2-amino-2-oxoethyl group Chemical group [H]C([*])([H])C(=O)N([H])[H] 0.000 description 1
• GOJUJUVQIVIZAV-UHFFFAOYSA-N 2-amino-4,6-dichloropyrimidine-5-carbaldehyde Chemical group NC1=NC(Cl)=C(C=O)C(Cl)=N1 GOJUJUVQIVIZAV-UHFFFAOYSA-N 0.000 description 1
• PMUNIMVZCACZBB-UHFFFAOYSA-N 2-hydroxyethylazanium;chloride Chemical compound Cl.NCCO PMUNIMVZCACZBB-UHFFFAOYSA-N 0.000 description 1
• UAIUNKRWKOVEES-UHFFFAOYSA-N 3,3',5,5'-tetramethylbenzidine Chemical compound CC1=C(N)C(C)=CC(C=2C=C(C)C(N)=C(C)C=2)=C1 UAIUNKRWKOVEES-UHFFFAOYSA-N 0.000 description 1
• YRNWIFYIFSBPAU-UHFFFAOYSA-N 4-[4-(dimethylamino)phenyl]-n,n-dimethylaniline Chemical compound C1=CC(N(C)C)=CC=C1C1=CC=C(N(C)C)C=C1 YRNWIFYIFSBPAU-UHFFFAOYSA-N 0.000 description 1
• WUBBRNOQWQTFEX-UHFFFAOYSA-N 4-aminosalicylic acid Chemical compound NC1=CC=C(C(O)=O)C(O)=C1 WUBBRNOQWQTFEX-UHFFFAOYSA-N 0.000 description 1
• 108010029607 4-nitrophenyl-alpha-glucosidase Proteins 0.000 description 1
• 206010069754 Acquired gene mutation Diseases 0.000 description 1
• 208000024893 Acute lymphoblastic leukemia Diseases 0.000 description 1
• 208000014697 Acute lymphocytic leukaemia Diseases 0.000 description 1
• 208000031261 Acute myeloid leukaemia Diseases 0.000 description 1
• 102000011767 Acute-Phase Proteins Human genes 0.000 description 1
• 108010062271 Acute-Phase Proteins Proteins 0.000 description 1
• 108010088751 Albumins Proteins 0.000 description 1
• 102000009027 Albumins Human genes 0.000 description 1
• 108700028369 Alleles Proteins 0.000 description 1
• 108010063104 Apoptosis Regulatory Proteins Proteins 0.000 description 1
• 102000010565 Apoptosis Regulatory Proteins Human genes 0.000 description 1
• DCXYFEDJOCDNAF-UHFFFAOYSA-N Asparagine Natural products OC(=O)C(N)CC(N)=O DCXYFEDJOCDNAF-UHFFFAOYSA-N 0.000 description 1
• 241000416162 Astragalus gummifer Species 0.000 description 1
• 108090001008 Avidin Proteins 0.000 description 1
• 208000010839 B-cell chronic lymphocytic leukemia Diseases 0.000 description 1
• VOVIALXJUBGFJZ-KWVAZRHASA-N Budesonide Chemical compound C1CC2=CC(=O)C=C[C@]2(C)[C@@H]2[C@@H]1[C@@H]1C[C@H]3OC(CCC)O[C@@]3(C(=O)CO)[C@@]1(C)C[C@@H]2O VOVIALXJUBGFJZ-KWVAZRHASA-N 0.000 description 1
• 108010074051 C-Reactive Protein Proteins 0.000 description 1
• 102100032752 C-reactive protein Human genes 0.000 description 1
• 101150013553 CD40 gene Proteins 0.000 description 1
• 101000918297 Caenorhabditis elegans Exostosin-2 homolog Proteins 0.000 description 1
• UXVMQQNJUSDDNG-UHFFFAOYSA-L Calcium chloride Chemical compound [Cl-].[Cl-].[Ca+2] UXVMQQNJUSDDNG-UHFFFAOYSA-L 0.000 description 1
• 241000282472 Canis lupus familiaris Species 0.000 description 1
• 102100035360 Cerebellar degeneration-related antigen 1 Human genes 0.000 description 1
• 102000008186 Collagen Human genes 0.000 description 1
• 108010035532 Collagen Proteins 0.000 description 1
• 102000016917 Complement C1 Human genes 0.000 description 1
• 108010028774 Complement C1 Proteins 0.000 description 1
• 108091035707 Consensus sequence Proteins 0.000 description 1
• 229920002261 Corn starch Polymers 0.000 description 1
• 241000699802 Cricetulus griseus Species 0.000 description 1
• 229930105110 Cyclosporin A Natural products 0.000 description 1
• 102100039498 Cytotoxic T-lymphocyte protein 4 Human genes 0.000 description 1
• FBPFZTCFMRRESA-FSIIMWSLSA-N D-Glucitol Natural products OC[C@H](O)[C@H](O)[C@@H](O)[C@H](O)CO FBPFZTCFMRRESA-FSIIMWSLSA-N 0.000 description 1
• FBPFZTCFMRRESA-KVTDHHQDSA-N D-Mannitol Chemical compound OC[C@@H](O)[C@@H](O)[C@H](O)[C@H](O)CO FBPFZTCFMRRESA-KVTDHHQDSA-N 0.000 description 1
• FBPFZTCFMRRESA-JGWLITMVSA-N D-glucitol Chemical compound OC[C@H](O)[C@@H](O)[C@H](O)[C@H](O)CO FBPFZTCFMRRESA-JGWLITMVSA-N 0.000 description 1
• SHZGCJCMOBCMKK-UHFFFAOYSA-N D-mannomethylose Natural products CC1OC(O)C(O)C(O)C1O SHZGCJCMOBCMKK-UHFFFAOYSA-N 0.000 description 1
• 230000004543 DNA replication Effects 0.000 description 1
• 108010014303 DNA-directed DNA polymerase Proteins 0.000 description 1
• 102000016928 DNA-directed DNA polymerase Human genes 0.000 description 1
• 241000238557 Decapoda Species 0.000 description 1
• 238000009007 Diagnostic Kit Methods 0.000 description 1
• 102100031111 Disintegrin and metalloproteinase domain-containing protein 17 Human genes 0.000 description 1
• 206010059866 Drug resistance Diseases 0.000 description 1
• 102100025137 Early activation antigen CD69 Human genes 0.000 description 1
• 229940122858 Elastase inhibitor Drugs 0.000 description 1
• 241000196324 Embryophyta Species 0.000 description 1
• 102400000792 Endothelial monocyte-activating polypeptide 2 Human genes 0.000 description 1
• 102400001368 Epidermal growth factor Human genes 0.000 description 1
• 101800003838 Epidermal growth factor Proteins 0.000 description 1
• 241000283086 Equidae Species 0.000 description 1
• 241000588724 Escherichia coli Species 0.000 description 1
• 101000759376 Escherichia phage Mu Tail sheath protein Proteins 0.000 description 1
• 150000000918 Europium Chemical class 0.000 description 1
• 108010007577 Exodeoxyribonuclease I Proteins 0.000 description 1
• 108010008177 Fd immunoglobulins Proteins 0.000 description 1
• 229940123414 Folate antagonist Drugs 0.000 description 1
• PNNNRSAQSRJVSB-SLPGGIOYSA-N Fucose Natural products C[C@H](O)[C@@H](O)[C@H](O)[C@H](O)C=O PNNNRSAQSRJVSB-SLPGGIOYSA-N 0.000 description 1
• 230000005526 G1 to G0 transition Effects 0.000 description 1
• 108060003306 Galactosyltransferase Proteins 0.000 description 1
• 102000030902 Galactosyltransferase Human genes 0.000 description 1
• 108700028146 Genetic Enhancer Elements Proteins 0.000 description 1
• 108700007698 Genetic Terminator Regions Proteins 0.000 description 1
• 229930182566 Gentamicin Natural products 0.000 description 1
• CEAZRRDELHUEMR-URQXQFDESA-N Gentamicin Chemical compound O1[C@H](C(C)NC)CC[C@@H](N)[C@H]1O[C@H]1[C@H](O)[C@@H](O[C@@H]2[C@@H]([C@@H](NC)[C@@](C)(O)CO2)O)[C@H](N)C[C@@H]1N CEAZRRDELHUEMR-URQXQFDESA-N 0.000 description 1
• 108010072051 Glatiramer Acetate Proteins 0.000 description 1
• 102000006395 Globulins Human genes 0.000 description 1
• 108010044091 Globulins Proteins 0.000 description 1
• 108010051696 Growth Hormone Proteins 0.000 description 1
• 239000007995 HEPES buffer Substances 0.000 description 1
• 241000238631 Hexapoda Species 0.000 description 1
• 208000017604 Hodgkin disease Diseases 0.000 description 1
• 208000021519 Hodgkin lymphoma Diseases 0.000 description 1
• 208000010747 Hodgkins lymphoma Diseases 0.000 description 1
• 101000889276 Homo sapiens Cytotoxic T-lymphocyte protein 4 Proteins 0.000 description 1
• 101000934374 Homo sapiens Early activation antigen CD69 Proteins 0.000 description 1
• 101100072407 Homo sapiens IL21R gene Proteins 0.000 description 1
• 101000599852 Homo sapiens Intercellular adhesion molecule 1 Proteins 0.000 description 1
• 101000599940 Homo sapiens Interferon gamma Proteins 0.000 description 1
• 101000934346 Homo sapiens T-cell surface antigen CD2 Proteins 0.000 description 1
• 101000946843 Homo sapiens T-cell surface glycoprotein CD8 alpha chain Proteins 0.000 description 1
• 101000800116 Homo sapiens Thy-1 membrane glycoprotein Proteins 0.000 description 1
• 101000851376 Homo sapiens Tumor necrosis factor receptor superfamily member 8 Proteins 0.000 description 1
• 101000997835 Homo sapiens Tyrosine-protein kinase JAK1 Proteins 0.000 description 1
• 101000964713 Homo sapiens Zinc finger protein 395 Proteins 0.000 description 1
• 102000003839 Human Proteins Human genes 0.000 description 1
• 108090000144 Human Proteins Proteins 0.000 description 1
• 239000003458 I kappa b kinase inhibitor Substances 0.000 description 1
• HEFNNWSXXWATRW-UHFFFAOYSA-N Ibuprofen Chemical compound CC(C)CC1=CC=C(C(C)C(O)=O)C=C1 HEFNNWSXXWATRW-UHFFFAOYSA-N 0.000 description 1
• 101710177940 IgG receptor FcRn large subunit p51 Proteins 0.000 description 1
• 102100026120 IgG receptor FcRn large subunit p51 Human genes 0.000 description 1
• 108010009817 Immunoglobulin Constant Regions Proteins 0.000 description 1
• 102000009786 Immunoglobulin Constant Regions Human genes 0.000 description 1
• 108010091135 Immunoglobulin Fc Fragments Proteins 0.000 description 1
• 102000018071 Immunoglobulin Fc Fragments Human genes 0.000 description 1
• 108010008212 Integrin alpha4beta1 Proteins 0.000 description 1
• 102000001617 Interferon Receptors Human genes 0.000 description 1
• 108010054267 Interferon Receptors Proteins 0.000 description 1
• 102100037850 Interferon gamma Human genes 0.000 description 1
• 102000003996 Interferon-beta Human genes 0.000 description 1
• 108090000467 Interferon-beta Proteins 0.000 description 1
• 102000051628 Interleukin-1 receptor antagonist Human genes 0.000 description 1
• 108700021006 Interleukin-1 receptor antagonist Proteins 0.000 description 1
• 102400000027 Interleukin-1 receptor type 2, soluble form Human genes 0.000 description 1
• 101800001003 Interleukin-1 receptor type 2, soluble form Proteins 0.000 description 1
• 102000004551 Interleukin-10 Receptors Human genes 0.000 description 1
• 108010017550 Interleukin-10 Receptors Proteins 0.000 description 1
• 102000004559 Interleukin-13 Receptors Human genes 0.000 description 1
• 108010017511 Interleukin-13 Receptors Proteins 0.000 description 1
• 101800003050 Interleukin-16 Proteins 0.000 description 1
• 102000049772 Interleukin-16 Human genes 0.000 description 1
• 102000004557 Interleukin-18 Receptors Human genes 0.000 description 1
• 108010017537 Interleukin-18 Receptors Proteins 0.000 description 1
• 102100035017 Interleukin-18-binding protein Human genes 0.000 description 1
• 101710205006 Interleukin-18-binding protein Proteins 0.000 description 1
• 108010065637 Interleukin-23 Proteins 0.000 description 1
• 102000010787 Interleukin-4 Receptors Human genes 0.000 description 1
• 108010038486 Interleukin-4 Receptors Proteins 0.000 description 1
• QNAYBMKLOCPYGJ-REOHCLBHSA-N L-alanine Chemical compound C[C@H](N)C(O)=O QNAYBMKLOCPYGJ-REOHCLBHSA-N 0.000 description 1
• DCXYFEDJOCDNAF-REOHCLBHSA-N L-asparagine Chemical compound OC(=O)[C@@H](N)CC(N)=O DCXYFEDJOCDNAF-REOHCLBHSA-N 0.000 description 1
• CKLJMWTZIZZHCS-REOHCLBHSA-N L-aspartic acid Chemical compound OC(=O)[C@@H](N)CC(O)=O CKLJMWTZIZZHCS-REOHCLBHSA-N 0.000 description 1
• COLNVLDHVKWLRT-QMMMGPOBSA-N L-phenylalanine Chemical compound OC(=O)[C@@H](N)CC1=CC=CC=C1 COLNVLDHVKWLRT-QMMMGPOBSA-N 0.000 description 1
• QIVBCDIJIAJPQS-VIFPVBQESA-N L-tryptophane Chemical compound C1=CC=C2C(C[C@H](N)C(O)=O)=CNC2=C1 QIVBCDIJIAJPQS-VIFPVBQESA-N 0.000 description 1
• OUYCCCASQSFEME-QMMMGPOBSA-N L-tyrosine Chemical compound OC(=O)[C@@H](N)CC1=CC=C(O)C=C1 OUYCCCASQSFEME-QMMMGPOBSA-N 0.000 description 1
• GUBGYTABKSRVRQ-QKKXKWKRSA-N Lactose Natural products OC[C@H]1O[C@@H](O[C@H]2[C@H](O)[C@@H](O)C(O)O[C@@H]2CO)[C@H](O)[C@@H](O)[C@H]1O GUBGYTABKSRVRQ-QKKXKWKRSA-N 0.000 description 1
• 102000004856 Lectins Human genes 0.000 description 1
• 108090001090 Lectins Proteins 0.000 description 1
• 241000270322 Lepidosauria Species 0.000 description 1
• 102000016267 Leptin Human genes 0.000 description 1
• 108010092277 Leptin Proteins 0.000 description 1
• NNJVILVZKWQKPM-UHFFFAOYSA-N Lidocaine Chemical compound CCN(CC)CC(=O)NC1=C(C)C=CC=C1C NNJVILVZKWQKPM-UHFFFAOYSA-N 0.000 description 1
• 239000000867 Lipoxygenase Inhibitor Substances 0.000 description 1
• 229940122142 Lipoxygenase inhibitor Drugs 0.000 description 1
• 229930195725 Mannitol Natural products 0.000 description 1
• 102100025315 Mannosyl-oligosaccharide glucosidase Human genes 0.000 description 1
• ZRVUJXDFFKFLMG-UHFFFAOYSA-N Meloxicam Chemical compound OC=1C2=CC=CC=C2S(=O)(=O)N(C)C=1C(=O)NC1=NC=C(C)S1 ZRVUJXDFFKFLMG-UHFFFAOYSA-N 0.000 description 1
• 229920000168 Microcrystalline cellulose Polymers 0.000 description 1
• 102100026907 Mitogen-activated protein kinase kinase kinase 8 Human genes 0.000 description 1
• 101710164353 Mitogen-activated protein kinase kinase kinase 8 Proteins 0.000 description 1
• 229940121849 Mitotic inhibitor Drugs 0.000 description 1
• 241000699660 Mus musculus Species 0.000 description 1
• OVRNDRQMDRJTHS-UHFFFAOYSA-N N-acelyl-D-glucosamine Natural products CC(=O)NC1C(O)OC(CO)C(O)C1O OVRNDRQMDRJTHS-UHFFFAOYSA-N 0.000 description 1
• MBLBDJOUHNCFQT-LXGUWJNJSA-N N-acetylglucosamine Natural products CC(=O)N[C@@H](C=O)[C@@H](O)[C@H](O)[C@H](O)CO MBLBDJOUHNCFQT-LXGUWJNJSA-N 0.000 description 1
• 230000004988 N-glycosylation Effects 0.000 description 1
• 108091007491 NSP3 Papain-like protease domains Proteins 0.000 description 1
• CMWTZPSULFXXJA-UHFFFAOYSA-N Naproxen Natural products C1=C(C(C)C(O)=O)C=CC2=CC(OC)=CC=C21 CMWTZPSULFXXJA-UHFFFAOYSA-N 0.000 description 1
• 208000015914 Non-Hodgkin lymphomas Diseases 0.000 description 1
• 108010051791 Nuclear Antigens Proteins 0.000 description 1
• 102000019040 Nuclear Antigens Human genes 0.000 description 1
• 102100034925 P-selectin glycoprotein ligand 1 Human genes 0.000 description 1
• 101710137390 P-selectin glycoprotein ligand 1 Proteins 0.000 description 1
• 101150000187 PTGS2 gene Proteins 0.000 description 1
• 208000027190 Peripheral T-cell lymphomas Diseases 0.000 description 1
• 108010064785 Phospholipases Proteins 0.000 description 1
• 102000015439 Phospholipases Human genes 0.000 description 1
• 206010035226 Plasma cell myeloma Diseases 0.000 description 1
• 241000276498 Pollachius virens Species 0.000 description 1
• 229920002732 Polyanhydride Polymers 0.000 description 1
• 229920000954 Polyglycolide Polymers 0.000 description 1
• 229920001710 Polyorthoester Polymers 0.000 description 1
• 229920001213 Polysorbate 20 Polymers 0.000 description 1
• 208000006664 Precursor Cell Lymphoblastic Leukemia-Lymphoma Diseases 0.000 description 1
• CZPWVGJYEJSRLH-UHFFFAOYSA-N Pyrimidine Chemical compound C1=CN=CN=C1 CZPWVGJYEJSRLH-UHFFFAOYSA-N 0.000 description 1
• 239000012980 RPMI-1640 medium Substances 0.000 description 1
• 108010008281 Recombinant Fusion Proteins Proteins 0.000 description 1
• 102000007056 Recombinant Fusion Proteins Human genes 0.000 description 1
• 108010081734 Ribonucleoproteins Proteins 0.000 description 1
• 102000004389 Ribonucleoproteins Human genes 0.000 description 1
• 108010044012 STAT1 Transcription Factor Proteins 0.000 description 1
• 102000003838 Sialyltransferases Human genes 0.000 description 1
• 108090000141 Sialyltransferases Proteins 0.000 description 1
• 102100029904 Signal transducer and activator of transcription 1-alpha/beta Human genes 0.000 description 1
• VYPSYNLAJGMNEJ-UHFFFAOYSA-N Silicium dioxide Chemical compound O=[Si]=O VYPSYNLAJGMNEJ-UHFFFAOYSA-N 0.000 description 1
• 108010003723 Single-Domain Antibodies Proteins 0.000 description 1
• DWAQJAXMDSEUJJ-UHFFFAOYSA-M Sodium bisulfite Chemical compound [Na+].OS([O-])=O DWAQJAXMDSEUJJ-UHFFFAOYSA-M 0.000 description 1
• FKNQFGJONOIPTF-UHFFFAOYSA-N Sodium cation Chemical compound [Na+] FKNQFGJONOIPTF-UHFFFAOYSA-N 0.000 description 1
• 102100038803 Somatotropin Human genes 0.000 description 1
• 238000002105 Southern blotting Methods 0.000 description 1
• 229920002472 Starch Polymers 0.000 description 1
• 108010090804 Streptavidin Proteins 0.000 description 1
• 229930006000 Sucrose Natural products 0.000 description 1
• CZMRCDWAGMRECN-UGDNZRGBSA-N Sucrose Chemical compound O[C@H]1[C@H](O)[C@@H](CO)O[C@@]1(CO)O[C@@H]1[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O1 CZMRCDWAGMRECN-UGDNZRGBSA-N 0.000 description 1
• 241000282887 Suidae Species 0.000 description 1
• 108091008874 T cell receptors Proteins 0.000 description 1
• 102000016266 T-Cell Antigen Receptors Human genes 0.000 description 1
• 208000031672 T-Cell Peripheral Lymphoma Diseases 0.000 description 1
• 102100025237 T-cell surface antigen CD2 Human genes 0.000 description 1
• 102100033523 Thy-1 membrane glycoprotein Human genes 0.000 description 1
• 229920001615 Tragacanth Polymers 0.000 description 1
• 102000000887 Transcription factor STAT Human genes 0.000 description 1
• 108050007918 Transcription factor STAT Proteins 0.000 description 1
• 102000004357 Transferases Human genes 0.000 description 1
• 108090000992 Transferases Proteins 0.000 description 1
• 102000004887 Transforming Growth Factor beta Human genes 0.000 description 1
• 108090001012 Transforming Growth Factor beta Proteins 0.000 description 1
• QIVBCDIJIAJPQS-UHFFFAOYSA-N Tryptophan Natural products C1=CC=C2C(CC(N)C(O)=O)=CNC2=C1 QIVBCDIJIAJPQS-UHFFFAOYSA-N 0.000 description 1
• 102100040245 Tumor necrosis factor receptor superfamily member 5 Human genes 0.000 description 1
• 102100036857 Tumor necrosis factor receptor superfamily member 8 Human genes 0.000 description 1
• 102100033438 Tyrosine-protein kinase JAK1 Human genes 0.000 description 1
• 108091008605 VEGF receptors Proteins 0.000 description 1
• 241000700618 Vaccinia virus Species 0.000 description 1
• 206010046865 Vaccinia virus infection Diseases 0.000 description 1
• 108010000134 Vascular Cell Adhesion Molecule-1 Proteins 0.000 description 1
• 102000009484 Vascular Endothelial Growth Factor Receptors Human genes 0.000 description 1
• 102100023543 Vascular cell adhesion protein 1 Human genes 0.000 description 1
• 241000251539 Vertebrata <Metazoa> Species 0.000 description 1
• 241000700605 Viruses Species 0.000 description 1
• 238000012452 Xenomouse strains Methods 0.000 description 1
• 102100040733 Zinc finger protein 395 Human genes 0.000 description 1
• 230000002159 abnormal effect Effects 0.000 description 1
• 238000002835 absorbance Methods 0.000 description 1
• 239000003070 absorption delaying agent Substances 0.000 description 1
• 150000007513 acids Chemical class 0.000 description 1
• 239000013543 active substance Substances 0.000 description 1
• 239000002671 adjuvant Substances 0.000 description 1
• 230000002411 adverse Effects 0.000 description 1
• 239000000443 aerosol Substances 0.000 description 1
• 238000000246 agarose gel electrophoresis Methods 0.000 description 1
• 230000002776 aggregation Effects 0.000 description 1
• 238000004220 aggregation Methods 0.000 description 1
• 239000000783 alginic acid Substances 0.000 description 1
• 235000010443 alginic acid Nutrition 0.000 description 1
• 229920000615 alginic acid Polymers 0.000 description 1
• 229960001126 alginic acid Drugs 0.000 description 1
• 150000004781 alginic acids Chemical class 0.000 description 1
• JMLGXYWHNOKLBE-HOTXNYTESA-A alicaforsen sodium Chemical compound [Na+].[Na+].[Na+].[Na+].[Na+].[Na+].[Na+].[Na+].[Na+].[Na+].[Na+].[Na+].[Na+].[Na+].[Na+].[Na+].[Na+].[Na+].[Na+].O=C1NC(=O)C(C)=CN1[C@@H]1O[C@H](COP([O-])(=S)O[C@@H]2[C@H](O[C@H](C2)N2C(N=C(N)C=C2)=O)COP([O-])(=S)O[C@@H]2[C@H](O[C@H](C2)N2C3=C(C(NC(N)=N3)=O)N=C2)COP([O-])(=S)O[C@@H]2[C@H](O[C@H](C2)N2C3=NC=NC(N)=C3N=C2)COP([O-])(=S)O[C@@H]2[C@H](O[C@H](C2)N2C3=NC=NC(N)=C3N=C2)COP([O-])(=S)O[C@@H]2[C@H](O[C@H](C2)N2C(N=C(N)C=C2)=O)COP([O-])(=S)O[C@@H]2[C@H](O[C@H](C2)N2C(N=C(N)C=C2)=O)COP([O-])(=S)O[C@@H]2[C@H](O[C@H](C2)N2C(N=C(N)C=C2)=O)COP([O-])(=S)O[C@@H]2[C@H](O[C@H](C2)N2C3=C(C(NC(N)=N3)=O)N=C2)CO)[C@@H](OP([O-])(=S)OC[C@@H]2[C@H](C[C@@H](O2)N2C3=C(C(NC(N)=N3)=O)N=C2)OP([O-])(=S)OC[C@@H]2[C@H](C[C@@H](O2)N2C3=C(C(NC(N)=N3)=O)N=C2)OP([O-])(=S)OC[C@@H]2[C@H](C[C@@H](O2)N2C(N=C(N)C=C2)=O)OP([O-])(=S)OC[C@@H]2[C@H](C[C@@H](O2)N2C3=NC=NC(N)=C3N=C2)OP([O-])(=S)OC[C@@H]2[C@H](C[C@@H](O2)N2C(NC(=O)C(C)=C2)=O)OP([O-])(=S)OC[C@@H]2[C@H](C[C@@H](O2)N2C(N=C(N)C=C2)=O)OP([O-])(=S)OC[C@@H]2[C@H](C[C@@H](O2)N2C(N=C(N)C=C2)=O)OP([O-])(=S)OC[C@@H]2[C@H](C[C@@H](O2)N2C3=C(C(NC(N)=N3)=O)N=C2)OP([O-])(=S)OC[C@@H]2[C@H](C[C@@H](O2)N2C(NC(=O)C(C)=C2)=O)OP([O-])(=S)OC[C@@H]2[C@H](C[C@@H](O2)N2C(N=C(N)C=C2)=O)OP([O-])(=S)OC[C@@H]2[C@H](C[C@@H](O2)N2C3=NC=NC(N)=C3N=C2)O)C1 JMLGXYWHNOKLBE-HOTXNYTESA-A 0.000 description 1
• 229960004909 aminosalicylic acid Drugs 0.000 description 1
• 230000003698 anagen phase Effects 0.000 description 1
• 229960004238 anakinra Drugs 0.000 description 1
• 230000033115 angiogenesis Effects 0.000 description 1
• 239000004037 angiogenesis inhibitor Substances 0.000 description 1
• 238000000137 annealing Methods 0.000 description 1
• 230000008485 antagonism Effects 0.000 description 1
• 229940124599 anti-inflammatory drug Drugs 0.000 description 1
• 230000000692 anti-sense effect Effects 0.000 description 1
• 230000000259 anti-tumor effect Effects 0.000 description 1
• 230000000890 antigenic effect Effects 0.000 description 1
• 230000003078 antioxidant effect Effects 0.000 description 1
• 125000003118 aryl group Chemical group 0.000 description 1
• 235000009582 asparagine Nutrition 0.000 description 1
• 229960001230 asparagine Drugs 0.000 description 1
• 235000003704 aspartic acid Nutrition 0.000 description 1
• 230000001363 autoimmune Effects 0.000 description 1
• 229960002170 azathioprine Drugs 0.000 description 1
• LMEKQMALGUDUQG-UHFFFAOYSA-N azathioprine Chemical compound CN1C=NC([N+]([O-])=O)=C1SC1=NC=NC2=C1NC=N2 LMEKQMALGUDUQG-UHFFFAOYSA-N 0.000 description 1
• 238000003705 background correction Methods 0.000 description 1
• 230000003385 bacteriostatic effect Effects 0.000 description 1
• 229960004168 balsalazide Drugs 0.000 description 1
• IPOKCKJONYRRHP-FMQUCBEESA-N balsalazide Chemical compound C1=CC(C(=O)NCCC(=O)O)=CC=C1\N=N\C1=CC=C(O)C(C(O)=O)=C1 IPOKCKJONYRRHP-FMQUCBEESA-N 0.000 description 1
• 230000004888 barrier function Effects 0.000 description 1
• 235000019445 benzyl alcohol Nutrition 0.000 description 1
• SQVRNKJHWKZAKO-UHFFFAOYSA-N beta-N-Acetyl-D-neuraminic acid Natural products CC(=O)NC1C(O)CC(O)(C(O)=O)OC1C(O)C(O)CO SQVRNKJHWKZAKO-UHFFFAOYSA-N 0.000 description 1
• OQFSQFPPLPISGP-UHFFFAOYSA-N beta-carboxyaspartic acid Natural products OC(=O)C(N)C(C(O)=O)C(O)=O OQFSQFPPLPISGP-UHFFFAOYSA-N 0.000 description 1
• 229920002988 biodegradable polymer Polymers 0.000 description 1
• 239000004621 biodegradable polymer Substances 0.000 description 1
• 230000033228 biological regulation Effects 0.000 description 1
• 239000012472 biological sample Substances 0.000 description 1
• 239000002981 blocking agent Substances 0.000 description 1
• 210000000601 blood cell Anatomy 0.000 description 1
• 230000017531 blood circulation Effects 0.000 description 1
• 239000001055 blue pigment Substances 0.000 description 1
• 210000000988 bone and bone Anatomy 0.000 description 1
• 210000002798 bone marrow cell Anatomy 0.000 description 1
• 239000012888 bovine serum Substances 0.000 description 1
• 229960004436 budesonide Drugs 0.000 description 1
• DQXBYHZEEUGOBF-UHFFFAOYSA-N but-3-enoic acid;ethene Chemical compound C=C.OC(=O)CC=C DQXBYHZEEUGOBF-UHFFFAOYSA-N 0.000 description 1
• 239000001110 calcium chloride Substances 0.000 description 1
• 229910001628 calcium chloride Inorganic materials 0.000 description 1
• 239000001506 calcium phosphate Substances 0.000 description 1
• 229910000389 calcium phosphate Inorganic materials 0.000 description 1
• 235000011010 calcium phosphates Nutrition 0.000 description 1
• 239000002775 capsule Substances 0.000 description 1
• 229940082638 cardiac stimulant phosphodiesterase inhibitors Drugs 0.000 description 1
• 239000000969 carrier Substances 0.000 description 1
• 210000000845 cartilage Anatomy 0.000 description 1
• 239000005018 casein Substances 0.000 description 1
• BECPQYXYKAMYBN-UHFFFAOYSA-N casein, tech. Chemical compound NCCCCC(C(O)=O)N=C(O)C(CC(O)=O)N=C(O)C(CCC(O)=N)N=C(O)C(CC(C)C)N=C(O)C(CCC(O)=O)N=C(O)C(CC(O)=O)N=C(O)C(CCC(O)=O)N=C(O)C(C(C)O)N=C(O)C(CCC(O)=N)N=C(O)C(CCC(O)=N)N=C(O)C(CCC(O)=N)N=C(O)C(CCC(O)=O)N=C(O)C(CCC(O)=O)N=C(O)C(COP(O)(O)=O)N=C(O)C(CCC(O)=N)N=C(O)C(N)CC1=CC=CC=C1 BECPQYXYKAMYBN-UHFFFAOYSA-N 0.000 description 1
• 235000021240 caseins Nutrition 0.000 description 1
• 229960000590 celecoxib Drugs 0.000 description 1
• RZEKVGVHFLEQIL-UHFFFAOYSA-N celecoxib Chemical compound C1=CC(C)=CC=C1C1=CC(C(F)(F)F)=NN1C1=CC=C(S(N)(=O)=O)C=C1 RZEKVGVHFLEQIL-UHFFFAOYSA-N 0.000 description 1
• 230000021164 cell adhesion Effects 0.000 description 1
• 230000032823 cell division Effects 0.000 description 1
• 230000010261 cell growth Effects 0.000 description 1
• 230000004709 cell invasion Effects 0.000 description 1
• 239000013592 cell lysate Substances 0.000 description 1
• 230000006041 cell recruitment Effects 0.000 description 1
• 239000006285 cell suspension Substances 0.000 description 1
• 230000033077 cellular process Effects 0.000 description 1
• 208000015114 central nervous system disease Diseases 0.000 description 1
• 238000005119 centrifugation Methods 0.000 description 1
• 229960003115 certolizumab pegol Drugs 0.000 description 1
• 239000002738 chelating agent Substances 0.000 description 1
• 238000012412 chemical coupling Methods 0.000 description 1
• 238000010382 chemical cross-linking Methods 0.000 description 1
• 229960004926 chlorobutanol Drugs 0.000 description 1
• BFPSDSIWYFKGBC-UHFFFAOYSA-N chlorotrianisene Chemical compound C1=CC(OC)=CC=C1C(Cl)=C(C=1C=CC(OC)=CC=1)C1=CC=C(OC)C=C1 BFPSDSIWYFKGBC-UHFFFAOYSA-N 0.000 description 1
• 229960003405 ciprofloxacin Drugs 0.000 description 1
• 230000004087 circulation Effects 0.000 description 1
• 238000004140 cleaning Methods 0.000 description 1
• 238000003776 cleavage reaction Methods 0.000 description 1
• 238000011260 co-administration Methods 0.000 description 1
• 238000000576 coating method Methods 0.000 description 1
• 229920001436 collagen Polymers 0.000 description 1
• 229940075614 colloidal silicon dioxide Drugs 0.000 description 1
• 238000004891 communication Methods 0.000 description 1
• 238000012875 competitive assay Methods 0.000 description 1
• 239000002299 complementary DNA Substances 0.000 description 1
• 230000009918 complex formation Effects 0.000 description 1
• 230000021615 conjugation Effects 0.000 description 1
• 210000002808 connective tissue Anatomy 0.000 description 1
• 108091036078 conserved sequence Proteins 0.000 description 1
• 238000010276 construction Methods 0.000 description 1
• 229940038717 copaxone Drugs 0.000 description 1
• 239000008120 corn starch Substances 0.000 description 1
• 230000000139 costimulatory effect Effects 0.000 description 1
• 239000006071 cream Substances 0.000 description 1
• 239000003431 cross linking reagent Substances 0.000 description 1
• 238000012258 culturing Methods 0.000 description 1
• 230000001186 cumulative effect Effects 0.000 description 1
• 230000001351 cycling effect Effects 0.000 description 1
• 125000000151 cysteine group Chemical group N[C@@H](CS)C(=O)* 0.000 description 1
• 230000009089 cytolysis Effects 0.000 description 1
• 230000001086 cytosolic effect Effects 0.000 description 1
• 239000000824 cytostatic agent Substances 0.000 description 1
• 230000001085 cytostatic effect Effects 0.000 description 1
• 230000003013 cytotoxicity Effects 0.000 description 1
• 231100000135 cytotoxicity Toxicity 0.000 description 1
• 239000002619 cytotoxin Substances 0.000 description 1
• 230000006378 damage Effects 0.000 description 1
• 230000007547 defect Effects 0.000 description 1
• 230000002950 deficient Effects 0.000 description 1
• 230000001934 delay Effects 0.000 description 1
• 238000013461 design Methods 0.000 description 1
• 230000001066 destructive effect Effects 0.000 description 1
• 238000011161 development Methods 0.000 description 1
• 230000018109 developmental process Effects 0.000 description 1
• 229960003957 dexamethasone Drugs 0.000 description 1
• UREBDLICKHMUKA-CXSFZGCWSA-N dexamethasone Chemical compound C1CC2=CC(=O)C=C[C@]2(C)[C@]2(F)[C@@H]1[C@@H]1C[C@@H](C)[C@@](C(=O)CO)(O)[C@@]1(C)C[C@@H]2O UREBDLICKHMUKA-CXSFZGCWSA-N 0.000 description 1
• 239000008121 dextrose Substances 0.000 description 1
• 239000010432 diamond Substances 0.000 description 1
• 229960001259 diclofenac Drugs 0.000 description 1
• DCOPUUMXTXDBNB-UHFFFAOYSA-N diclofenac Chemical compound OC(=O)CC1=CC=CC=C1NC1=C(Cl)C=CC=C1Cl DCOPUUMXTXDBNB-UHFFFAOYSA-N 0.000 description 1
• UGMCXQCYOVCMTB-UHFFFAOYSA-K dihydroxy(stearato)aluminium Chemical compound CCCCCCCCCCCCCCCCCC(=O)O[Al](O)O UGMCXQCYOVCMTB-UHFFFAOYSA-K 0.000 description 1
• 239000003085 diluting agent Substances 0.000 description 1
• 238000006471 dimerization reaction Methods 0.000 description 1
• 239000007884 disintegrant Substances 0.000 description 1
• 239000002612 dispersion medium Substances 0.000 description 1
• 230000002500 effect on skin Effects 0.000 description 1
• 239000012893 effector ligand Substances 0.000 description 1
• 239000003602 elastase inhibitor Substances 0.000 description 1
• 229940116977 epidermal growth factor Drugs 0.000 description 1
• 210000002919 epithelial cell Anatomy 0.000 description 1
• 210000003743 erythrocyte Anatomy 0.000 description 1
• 230000000925 erythroid effect Effects 0.000 description 1
• 239000005038 ethylene vinyl acetate Substances 0.000 description 1
• 210000003527 eukaryotic cell Anatomy 0.000 description 1
• 230000005284 excitation Effects 0.000 description 1
• 239000013604 expression vector Substances 0.000 description 1
• 235000013861 fat-free Nutrition 0.000 description 1
• 239000000796 flavoring agent Substances 0.000 description 1
• 235000019634 flavors Nutrition 0.000 description 1
• 238000000684 flow cytometry Methods 0.000 description 1
• 239000012530 fluid Substances 0.000 description 1
• 230000037406 food intake Effects 0.000 description 1
• 235000003599 food sweetener Nutrition 0.000 description 1
• 230000037433 frameshift Effects 0.000 description 1
• 125000000524 functional group Chemical group 0.000 description 1
• 229930182830 galactose Natural products 0.000 description 1
• 239000007789 gas Substances 0.000 description 1
• 238000003633 gene expression assay Methods 0.000 description 1
• 229960002518 gentamicin Drugs 0.000 description 1
• 108010050669 glucosidase I Proteins 0.000 description 1
• 229930182480 glucuronide Natural products 0.000 description 1
• 150000008134 glucuronides Chemical class 0.000 description 1
• 235000013922 glutamic acid Nutrition 0.000 description 1
• 239000004220 glutamic acid Substances 0.000 description 1
• 150000002334 glycols Chemical class 0.000 description 1
• 229930182470 glycoside Natural products 0.000 description 1
• 150000002338 glycosides Chemical class 0.000 description 1
• 125000003147 glycosyl group Chemical group 0.000 description 1
• 102000035122 glycosylated proteins Human genes 0.000 description 1
• 108091005608 glycosylated proteins Proteins 0.000 description 1
• 239000000122 growth hormone Substances 0.000 description 1
• 239000001963 growth medium Substances 0.000 description 1
• 238000003306 harvesting Methods 0.000 description 1
• 230000036541 health Effects 0.000 description 1
• 238000010438 heat treatment Methods 0.000 description 1
• 210000002443 helper t lymphocyte Anatomy 0.000 description 1
• 210000003958 hematopoietic stem cell Anatomy 0.000 description 1
• VBZWSGALLODQNC-UHFFFAOYSA-N hexafluoroacetone Chemical class FC(F)(F)C(=O)C(F)(F)F VBZWSGALLODQNC-UHFFFAOYSA-N 0.000 description 1
• 229940088597 hormone Drugs 0.000 description 1
• 239000005556 hormone Substances 0.000 description 1
• 102000056549 human Fv Human genes 0.000 description 1
• 108700005872 human Fv Proteins 0.000 description 1
• 102000057041 human TNF Human genes 0.000 description 1
• 229940048921 humira Drugs 0.000 description 1
• 229960001680 ibuprofen Drugs 0.000 description 1
• 230000036737 immune function Effects 0.000 description 1
• 230000003832 immune regulation Effects 0.000 description 1
• 238000002649 immunization Methods 0.000 description 1
• 238000003119 immunoblot Methods 0.000 description 1
• 238000010166 immunofluorescence Methods 0.000 description 1
• 230000002163 immunogen Effects 0.000 description 1
• 108010023260 immunoglobulin Fv Proteins 0.000 description 1
• 238000010324 immunological assay Methods 0.000 description 1
• 238000001114 immunoprecipitation Methods 0.000 description 1
• 230000001861 immunosuppressant effect Effects 0.000 description 1
• 238000007901 in situ hybridization Methods 0.000 description 1
• 238000000099 in vitro assay Methods 0.000 description 1
• 229910052738 indium Inorganic materials 0.000 description 1
• 229960000905 indomethacin Drugs 0.000 description 1
• 239000003701 inert diluent Substances 0.000 description 1
• 230000028709 inflammatory response Effects 0.000 description 1
• 238000001802 infusion Methods 0.000 description 1
• 238000012482 interaction analysis Methods 0.000 description 1
• 229960001388 interferon-beta Drugs 0.000 description 1
• 108090000681 interleukin 20 Proteins 0.000 description 1
• 102000044166 interleukin-18 binding protein Human genes 0.000 description 1
• 108010070145 interleukin-18 binding protein Proteins 0.000 description 1
• 229940047122 interleukins Drugs 0.000 description 1
• 210000000936 intestine Anatomy 0.000 description 1
• 238000007918 intramuscular administration Methods 0.000 description 1
• 201000010659 intrinsic asthma Diseases 0.000 description 1
• 238000002955 isolation Methods 0.000 description 1
• 230000002147 killing effect Effects 0.000 description 1
• 238000002372 labelling Methods 0.000 description 1
• 239000008101 lactose Substances 0.000 description 1
• 239000000787 lecithin Substances 0.000 description 1
• 235000010445 lecithin Nutrition 0.000 description 1
• 229940067606 lecithin Drugs 0.000 description 1
• 239000002523 lectin Substances 0.000 description 1
• 229940039781 leptin Drugs 0.000 description 1
• NRYBAZVQPHGZNS-ZSOCWYAHSA-N leptin Chemical compound O=C([C@H](CO)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CC(O)=O)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CCC(N)=O)NC(=O)[C@H](CC=1C2=CC=CC=C2NC=1)NC(=O)[C@H](CC(C)C)NC(=O)[C@@H](NC(=O)[C@H](CC(O)=O)NC(=O)[C@H](CCC(N)=O)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CO)NC(=O)CNC(=O)[C@H](CCC(N)=O)NC(=O)[C@@H](N)CC(C)C)CCSC)N1CCC[C@H]1C(=O)NCC(=O)N[C@@H](CS)C(O)=O NRYBAZVQPHGZNS-ZSOCWYAHSA-N 0.000 description 1
• 231100001231 less toxic Toxicity 0.000 description 1
• 231100000518 lethal Toxicity 0.000 description 1
• 230000001665 lethal effect Effects 0.000 description 1
• 229960004194 lidocaine Drugs 0.000 description 1
• 239000007937 lozenge Substances 0.000 description 1
• 239000000314 lubricant Substances 0.000 description 1
• 238000004020 luminiscence type Methods 0.000 description 1
• 210000004324 lymphatic system Anatomy 0.000 description 1
• 239000006166 lysate Substances 0.000 description 1
• 229940124302 mTOR inhibitor Drugs 0.000 description 1
• 235000019359 magnesium stearate Nutrition 0.000 description 1
• 230000036210 malignancy Effects 0.000 description 1
• 239000003628 mammalian target of rapamycin inhibitor Substances 0.000 description 1
• 210000005075 mammary gland Anatomy 0.000 description 1
• 239000000594 mannitol Substances 0.000 description 1
• 235000010355 mannitol Nutrition 0.000 description 1
• 108010083819 mannosyl-oligosaccharide 1,3 - 1,6-alpha-mannosidase Proteins 0.000 description 1
• 239000003550 marker Substances 0.000 description 1
• 208000020968 mature T-cell and NK-cell non-Hodgkin lymphoma Diseases 0.000 description 1
• 210000003593 megakaryocyte Anatomy 0.000 description 1
• 229960001929 meloxicam Drugs 0.000 description 1
• 238000002844 melting Methods 0.000 description 1
• 230000008018 melting Effects 0.000 description 1
• 108010000525 member 1 small inducible cytokine subfamily E Proteins 0.000 description 1
• 239000012528 membrane Substances 0.000 description 1
• 229960001428 mercaptopurine Drugs 0.000 description 1
• 239000004292 methyl p-hydroxybenzoate Substances 0.000 description 1
• 235000010270 methyl p-hydroxybenzoate Nutrition 0.000 description 1
• 229960002216 methylparaben Drugs 0.000 description 1
• 229960000282 metronidazole Drugs 0.000 description 1
• VAOCPAMSLUNLGC-UHFFFAOYSA-N metronidazole Chemical compound CC1=NC=C([N+]([O-])=O)N1CCO VAOCPAMSLUNLGC-UHFFFAOYSA-N 0.000 description 1
• 244000005700 microbiome Species 0.000 description 1
• 235000019813 microcrystalline cellulose Nutrition 0.000 description 1
• 239000008108 microcrystalline cellulose Substances 0.000 description 1
• 229940016286 microcrystalline cellulose Drugs 0.000 description 1
• 239000002829 mitogen activated protein kinase inhibitor Substances 0.000 description 1
• 230000000394 mitotic effect Effects 0.000 description 1
• ZAHQPTJLOCWVPG-UHFFFAOYSA-N mitoxantrone dihydrochloride Chemical compound Cl.Cl.O=C1C2=C(O)C=CC(O)=C2C(=O)C2=C1C(NCCNCCO)=CC=C2NCCNCCO ZAHQPTJLOCWVPG-UHFFFAOYSA-N 0.000 description 1
• 238000000302 molecular modelling Methods 0.000 description 1
• 239000000178 monomer Substances 0.000 description 1
• 150000002772 monosaccharides Chemical class 0.000 description 1
• 210000000214 mouth Anatomy 0.000 description 1
• 210000003007 myelin sheath Anatomy 0.000 description 1
• 201000000050 myeloid neoplasm Diseases 0.000 description 1
• 229950006780 n-acetylglucosamine Drugs 0.000 description 1
• KDGKTJGPFXIBEB-UHFFFAOYSA-N n-hydroxyformamide Chemical compound ONC=O KDGKTJGPFXIBEB-UHFFFAOYSA-N 0.000 description 1
• 210000004897 n-terminal region Anatomy 0.000 description 1
• 229960002009 naproxen Drugs 0.000 description 1
• CMWTZPSULFXXJA-VIFPVBQESA-N naproxen Chemical compound C1=C([C@H](C)C(O)=O)C=CC2=CC(OC)=CC=C21 CMWTZPSULFXXJA-VIFPVBQESA-N 0.000 description 1
• 239000007922 nasal spray Substances 0.000 description 1
• 239000006199 nebulizer Substances 0.000 description 1
• 230000017128 negative regulation of NF-kappaB transcription factor activity Effects 0.000 description 1
• 210000005170 neoplastic cell Anatomy 0.000 description 1
• 230000001613 neoplastic effect Effects 0.000 description 1
• 230000000626 neurodegenerative effect Effects 0.000 description 1
• 229910052757 nitrogen Inorganic materials 0.000 description 1
• 239000000041 non-steroidal anti-inflammatory agent Substances 0.000 description 1
• 231100000956 nontoxicity Toxicity 0.000 description 1
• 239000000346 nonvolatile oil Substances 0.000 description 1
• 229940046166 oligodeoxynucleotide Drugs 0.000 description 1
• 229920001542 oligosaccharide Polymers 0.000 description 1
• 150000002482 oligosaccharides Chemical class 0.000 description 1
• 229960004110 olsalazine Drugs 0.000 description 1
• QQBDLJCYGRGAKP-FOCLMDBBSA-N olsalazine Chemical compound C1=C(O)C(C(=O)O)=CC(\N=N\C=2C=C(C(O)=CC=2)C(O)=O)=C1 QQBDLJCYGRGAKP-FOCLMDBBSA-N 0.000 description 1
• 238000010397 one-hybrid screening Methods 0.000 description 1
• 210000000287 oocyte Anatomy 0.000 description 1
• 230000008816 organ damage Effects 0.000 description 1
• 230000003204 osmotic effect Effects 0.000 description 1
• 210000001672 ovary Anatomy 0.000 description 1
• 238000004806 packaging method and process Methods 0.000 description 1
• 230000001575 pathological effect Effects 0.000 description 1
• 239000008188 pellet Substances 0.000 description 1
• 102000014187 peptide receptors Human genes 0.000 description 1
• 108010011903 peptide receptors Proteins 0.000 description 1
• 238000010647 peptide synthesis reaction Methods 0.000 description 1
• 210000003819 peripheral blood mononuclear cell Anatomy 0.000 description 1
• 239000000825 pharmaceutical preparation Substances 0.000 description 1
• 229960003742 phenol Drugs 0.000 description 1
• COLNVLDHVKWLRT-UHFFFAOYSA-N phenylalanine Natural products OC(=O)C(N)CC1=CC=CC=C1 COLNVLDHVKWLRT-UHFFFAOYSA-N 0.000 description 1
• NBIIXXVUZAFLBC-UHFFFAOYSA-K phosphate Chemical compound [O-]P([O-])([O-])=O NBIIXXVUZAFLBC-UHFFFAOYSA-K 0.000 description 1
• 239000002571 phosphodiesterase inhibitor Substances 0.000 description 1
• 239000003428 phospholipase inhibitor Substances 0.000 description 1
• 230000026731 phosphorylation Effects 0.000 description 1
• 238000006366 phosphorylation reaction Methods 0.000 description 1
• 230000004962 physiological condition Effects 0.000 description 1
• 239000002504 physiological saline solution Substances 0.000 description 1
• 229960002702 piroxicam Drugs 0.000 description 1
• QYSPLQLAKJAUJT-UHFFFAOYSA-N piroxicam Chemical compound OC=1C2=CC=CC=C2S(=O)(=O)N(C)C=1C(=O)NC1=CC=CC=N1 QYSPLQLAKJAUJT-UHFFFAOYSA-N 0.000 description 1
• 210000002381 plasma Anatomy 0.000 description 1
• 230000036470 plasma concentration Effects 0.000 description 1
• 210000004180 plasmocyte Anatomy 0.000 description 1
• 229920001200 poly(ethylene-vinyl acetate) Polymers 0.000 description 1
• 229920000747 poly(lactic acid) Polymers 0.000 description 1
• 230000008488 polyadenylation Effects 0.000 description 1
• 239000004633 polyglycolic acid Substances 0.000 description 1
• 239000004626 polylactic acid Substances 0.000 description 1
• 229920005862 polyol Polymers 0.000 description 1
• 150000003077 polyols Chemical class 0.000 description 1
• 239000000256 polyoxyethylene sorbitan monolaurate Substances 0.000 description 1
• 235000010486 polyoxyethylene sorbitan monolaurate Nutrition 0.000 description 1
• 229920001451 polypropylene glycol Polymers 0.000 description 1
• 230000030716 positive regulation of phosphorylation Effects 0.000 description 1
• 230000016833 positive regulation of signal transduction Effects 0.000 description 1
• 231100000683 possible toxicity Toxicity 0.000 description 1
• 239000011698 potassium fluoride Substances 0.000 description 1
• 235000003270 potassium fluoride Nutrition 0.000 description 1
• 230000002265 prevention Effects 0.000 description 1
• 125000002924 primary amino group Chemical group [H]N([H])* 0.000 description 1
• 239000000651 prodrug Substances 0.000 description 1
• 229940002612 prodrug Drugs 0.000 description 1
• 230000000770 proinflammatory effect Effects 0.000 description 1
• 210000001236 prokaryotic cell Anatomy 0.000 description 1
• 230000002062 proliferating effect Effects 0.000 description 1
• 230000002035 prolonged effect Effects 0.000 description 1
• 239000003380 propellant Substances 0.000 description 1
• XJMOSONTPMZWPB-UHFFFAOYSA-M propidium iodide Chemical compound [I-].[I-].C12=CC(N)=CC=C2C2=CC=C(N)C=C2[N+](CCC[N+](C)(CC)CC)=C1C1=CC=CC=C1 XJMOSONTPMZWPB-UHFFFAOYSA-M 0.000 description 1
• QQONPFPTGQHPMA-UHFFFAOYSA-N propylene Natural products CC=C QQONPFPTGQHPMA-UHFFFAOYSA-N 0.000 description 1
• 125000004805 propylene group Chemical group [H]C([H])([H])C([H])([*:1])C([H])([H])[*:2] 0.000 description 1
• 239000012562 protein A resin Substances 0.000 description 1
• 238000000159 protein binding assay Methods 0.000 description 1
• 238000002331 protein detection Methods 0.000 description 1
• 108020003519 protein disulfide isomerase Proteins 0.000 description 1
• 230000027380 protein glycosylation in Golgi Effects 0.000 description 1
• 230000005664 protein glycosylation in endoplasmic reticulum Effects 0.000 description 1
• 238000004445 quantitative analysis Methods 0.000 description 1
• 239000012857 radioactive material Substances 0.000 description 1
• 238000003127 radioimmunoassay Methods 0.000 description 1
• 238000002708 random mutagenesis Methods 0.000 description 1
• 238000003259 recombinant expression Methods 0.000 description 1
• 210000003289 regulatory T cell Anatomy 0.000 description 1
• 229940116176 remicade Drugs 0.000 description 1
• 230000000241 respiratory effect Effects 0.000 description 1
• 208000023504 respiratory system disease Diseases 0.000 description 1
• 230000000284 resting effect Effects 0.000 description 1
• 238000012552 review Methods 0.000 description 1
• 238000002702 ribosome display Methods 0.000 description 1
• 230000007017 scission Effects 0.000 description 1
• 238000007423 screening assay Methods 0.000 description 1
• 238000002864 sequence alignment Methods 0.000 description 1
• 238000013207 serial dilution Methods 0.000 description 1
• 239000012679 serum free medium Substances 0.000 description 1
• 230000035939 shock Effects 0.000 description 1
• 125000005629 sialic acid group Chemical group 0.000 description 1
• 239000002356 single layer Substances 0.000 description 1
• 238000011125 single therapy Methods 0.000 description 1
• 238000002741 site-directed mutagenesis Methods 0.000 description 1
• 235000010267 sodium hydrogen sulphite Nutrition 0.000 description 1
• 229910001415 sodium ion Inorganic materials 0.000 description 1
• 239000001488 sodium phosphate Substances 0.000 description 1
• 229910000162 sodium phosphate Inorganic materials 0.000 description 1
• 229940054269 sodium pyruvate Drugs 0.000 description 1
• 230000000392 somatic effect Effects 0.000 description 1
• 230000037439 somatic mutation Effects 0.000 description 1
• 239000000600 sorbitol Substances 0.000 description 1
• 210000004989 spleen cell Anatomy 0.000 description 1
• 239000007921 spray Substances 0.000 description 1
• 239000008107 starch Substances 0.000 description 1
• 235000019698 starch Nutrition 0.000 description 1
• 238000003860 storage Methods 0.000 description 1
• 239000005720 sucrose Substances 0.000 description 1
• 150000005846 sugar alcohols Polymers 0.000 description 1
• 150000008163 sugars Chemical class 0.000 description 1
• 230000000153 supplemental effect Effects 0.000 description 1
• 239000000829 suppository Substances 0.000 description 1
• 239000004094 surface-active agent Substances 0.000 description 1
• 238000013268 sustained release Methods 0.000 description 1
• 239000012730 sustained-release form Substances 0.000 description 1
• 239000003765 sweetening agent Substances 0.000 description 1
• 230000002195 synergetic effect Effects 0.000 description 1
• 239000003826 tablet Substances 0.000 description 1
• QJJXYPPXXYFBGM-SHYZHZOCSA-N tacrolimus Natural products CO[C@H]1C[C@H](CC[C@@H]1O)C=C(C)[C@H]2OC(=O)[C@H]3CCCCN3C(=O)C(=O)[C@@]4(O)O[C@@H]([C@H](C[C@H]4C)OC)[C@@H](C[C@H](C)CC(=C[C@@H](CC=C)C(=O)C[C@H](O)[C@H]2C)C)OC QJJXYPPXXYFBGM-SHYZHZOCSA-N 0.000 description 1
• 229960003676 tenidap Drugs 0.000 description 1
• LXIKEPCNDFVJKC-QXMHVHEDSA-N tenidap Chemical compound C12=CC(Cl)=CC=C2N(C(=O)N)C(=O)\C1=C(/O)C1=CC=CS1 LXIKEPCNDFVJKC-QXMHVHEDSA-N 0.000 description 1
• RTKIYNMVFMVABJ-UHFFFAOYSA-L thimerosal Chemical compound [Na+].CC[Hg]SC1=CC=CC=C1C([O-])=O RTKIYNMVFMVABJ-UHFFFAOYSA-L 0.000 description 1
• 229940033663 thimerosal Drugs 0.000 description 1
• RYYWUUFWQRZTIU-UHFFFAOYSA-K thiophosphate Chemical compound [O-]P([O-])([O-])=S RYYWUUFWQRZTIU-UHFFFAOYSA-K 0.000 description 1
• PSWFFKRAVBDQEG-YGQNSOCVSA-N thymopentin Chemical compound NC(N)=NCCC[C@H](N)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CC(O)=O)C(=O)N[C@@H](C(C)C)C(=O)N[C@H](C(O)=O)CC1=CC=C(O)C=C1 PSWFFKRAVBDQEG-YGQNSOCVSA-N 0.000 description 1
• 230000000451 tissue damage Effects 0.000 description 1
• 230000000699 topical effect Effects 0.000 description 1
• 231100000331 toxic Toxicity 0.000 description 1
• 230000002588 toxic effect Effects 0.000 description 1
• 230000001988 toxicity Effects 0.000 description 1
• 231100000419 toxicity Toxicity 0.000 description 1
• 239000003053 toxin Substances 0.000 description 1
• 231100000765 toxin Toxicity 0.000 description 1
• 238000010361 transduction Methods 0.000 description 1
• 230000026683 transduction Effects 0.000 description 1
• 239000012096 transfection reagent Substances 0.000 description 1
• 230000009466 transformation Effects 0.000 description 1
• 230000001052 transient effect Effects 0.000 description 1
• 230000010474 transient expression Effects 0.000 description 1
• QORWJWZARLRLPR-UHFFFAOYSA-H tricalcium bis(phosphate) Chemical compound [Ca+2].[Ca+2].[Ca+2].[O-]P([O-])([O-])=O.[O-]P([O-])([O-])=O QORWJWZARLRLPR-UHFFFAOYSA-H 0.000 description 1
• RYFMWSXOAZQYPI-UHFFFAOYSA-K trisodium phosphate Chemical compound [Na+].[Na+].[Na+].[O-]P([O-])([O-])=O RYFMWSXOAZQYPI-UHFFFAOYSA-K 0.000 description 1
• 229940046728 tumor necrosis factor alpha inhibitor Drugs 0.000 description 1
• 239000002451 tumor necrosis factor inhibitor Substances 0.000 description 1
• OUYCCCASQSFEME-UHFFFAOYSA-N tyrosine Natural products OC(=O)C(N)CC1=CC=C(O)C=C1 OUYCCCASQSFEME-UHFFFAOYSA-N 0.000 description 1
• 238000000108 ultra-filtration Methods 0.000 description 1
• 241000701447 unidentified baculovirus Species 0.000 description 1
• 241001515965 unidentified phage Species 0.000 description 1
• VBEQCZHXXJYVRD-GACYYNSASA-N uroanthelone Chemical compound C([C@@H](C(=O)N[C@H](C(=O)N[C@@H](CS)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H](CS)C(=O)N[C@H](C(=O)N[C@@H]([C@@H](C)CC)C(=O)NCC(=O)N[C@@H](CC=1C=CC(O)=CC=1)C(=O)N[C@@H](CO)C(=O)NCC(=O)N[C@@H](CC(O)=O)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CS)C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@@H]([C@@H](C)O)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CC(O)=O)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CC=1C2=CC=CC=C2NC=1)C(=O)N[C@@H](CC=1C2=CC=CC=C2NC=1)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCCNC(N)=N)C(O)=O)C(C)C)[C@@H](C)O)NC(=O)[C@H](CO)NC(=O)[C@H](CC(O)=O)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CO)NC(=O)[C@H](CCC(O)=O)NC(=O)[C@@H](NC(=O)[C@H](CC=1NC=NC=1)NC(=O)[C@H](CCSC)NC(=O)[C@H](CS)NC(=O)[C@@H](NC(=O)CNC(=O)CNC(=O)[C@H](CC(N)=O)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CS)NC(=O)[C@H](CC=1C=CC(O)=CC=1)NC(=O)CNC(=O)[C@H](CC(O)=O)NC(=O)[C@H](CC=1C=CC(O)=CC=1)NC(=O)[C@H](CO)NC(=O)[C@H](CO)NC(=O)[C@H]1N(CCC1)C(=O)[C@H](CS)NC(=O)CNC(=O)[C@H]1N(CCC1)C(=O)[C@H](CC=1C=CC(O)=CC=1)NC(=O)[C@H](CO)NC(=O)[C@@H](N)CC(N)=O)C(C)C)[C@@H](C)CC)C1=CC=C(O)C=C1 VBEQCZHXXJYVRD-GACYYNSASA-N 0.000 description 1
• 229960005486 vaccine Drugs 0.000 description 1
• 208000007089 vaccinia Diseases 0.000 description 1
• 230000003612 virological effect Effects 0.000 description 1
• 238000001262 western blot Methods 0.000 description 1
• 238000002424 x-ray crystallography Methods 0.000 description 1
• 210000005253 yeast cell Anatomy 0.000 description 1